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ABSTRACT 
Currently in the drug development process there is a growing awareness of the need to 
utilise a biomarker strategy which would allow compounds to be developed in a more 
efficient way with improved safety and pharmacology. Technologies which can 
evaluate, validate and monitor biomarkers in a cost effective and efficient manner are 
a necessity if such a biomarker strategy is to be properly implemented. In this thesis 
the development, validation and implementation of a protein microarray for 
quantitative and simultaneous analysis of proteins is described. In order to 
demonstrate the feasibility of this approach, Rheumatoid arthritis (RA) was chosen as 
a model for proof of concept. Based on the current literature, seven proteins thought 
to be associated with the development and progression of RA were selected. Initially, 
a protein microarray was developed on a glass chip treated either with a self 
assembled monolayer (SAM) of octadecyl phosphoric acid ester (ODP) or with poly-
L-lysine. SAM showed its superiority over poly-L-lysine by generating more 
homogenous and less variable spots. However, the process of coating the chip with 
the SAM was time consuming and expensive. Moreover, assay processing was 
entirely performed manually and could not be automated without a significant 
investment of time and resources. As a result, high inter-chip variability was observed 
preventing sensitive, quantitative and reproducible analysis to be performed. An 
attempt was, therefore, undertaken to develop an alternative microarray platform. The 
appearance on the market of long neck tips for antibody printing devices, provided the 
option of using established polystyrene 96-well plates as the solid support for 
developing a fully automated microarray format. The development process involved 
reagent selection, printing protocol optimization, matrix investigation, assay protocol 
establishment, and detection system evaluation. The robustness and reproducibility of 
the methodology was investigated using the Food and Drug Administration (FDA) 
regulatory guidelines for pharmacokinetic assay validation, in which a spike-recovery 
validation test was elaborated and run over 3 days. The method was shown to be both 
quantitative and reproducible, with an assay accuracy between 70-130%, and assay 
precision less than 30%. Importantly, the working range for each assay covered the 
relevant physiological concentrations. In addition, protein microarray performance 
was compared with the classical ELISA approach. Sera collected from a total of 78 
individuals representing either rheumatic or healthy patients were measured using 
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both approaches. Correlation coefficients (R2) between the two technologies was 
calculated for each analyte giving: 0.90 for A, 0.60 for B, 0.93 for C, 0.96 for D, 0.94 
for E and 0.95 for F. Finally, the developed protein microarray was used to compare 
the analyte concentration levels between patients with RA and other rheumatic 
diseases. Significant differences in the serum concentration of B (p<0.0022), C 
(p<0.0107), E (p<0.0024) and F (p<0.0057) between RA and other arthritic patients 
were observed. In conclusion, the obtained results demonstrate the applicability of the 
developed protein microarray for quantitative and simultaneous analysis of the 
selected RA-related proteins in clinical samples. It is anticipated that miniaturized and 
multiplexed immunoassays which allow for the rapid evaluation of multiple analytes 
in a single sample, will represent a valuable tool for validating and monitoring 
biomarkers in the drug development process. 
   vii 
1 General Introduction 
The completion of the human genome project, and sequencing of additional genomes 
served to drive the development of new innovative technologies for genome-wide 
expression profiling (Kumble 2003). These so called “-omic” technologies, such as 
genomics and proteomics, have made it possible to follow transcriptional and 
translational events of genes and even the entire genome in response to biological 
processes (Hegde, White, & Debouck 2003). The “-omic” technologies are being 
increasingly used in the pharmaceutical industry at all levels of drug discovery and 
development, and commonly applied for the discovery of new drug targets, 
identification of drug efficacy and toxicity biomarkers, investigations into 
mechanisms of drug action and toxicity, and prioritization of new drugs (Colburn 
2003; Guerreiro et al. 2003). This is exemplified by DNA microarray technologies 
(genomics) that allow for the high throughput quantitative comparison of the 
transcriptional activity of potentially thousands of genes in a single experiment 
(DeRisi, Iyer, & Brown 1997). Complex molecular perturbations occurring during the 
onset of disease and progression, and therapeutic intervention can be thoroughly 
interrogated from a multitude of target organs and cells, thereby, providing a more 
holistic approach to biological responses.  
 
It is now accepted, however, that changes at the mRNA level are not necessarily 
proportional to changes at the protein level because of differences in rates of protein 
translation and degradation (Griffin et al. 2002). Furthermore, nucleotide screens are 
unable to provide information on the post-translational modifications of a protein, 
which may be critical for a protein's function (Kumble 2003). After all, it is the 
protein and not the mRNA that is the ultimate, biologically functional entity, 
providing the cellular function, whether it be for communication, metabolism or 
building cellular architecture. Therefore, there is a clear need to analyse the proteome 
activity of a biological sample and to complement this with genomics in order to 
obtain a higher level of understanding regarding the function of highly complex 
cellular networks. 
 
Proteomics is a complementary approach to genomics, and encompasses protein 
analysis technologies which deals with the global separation, quantification and 
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functional characterisation of expressed proteins. Techniques like mass spectrometry 
in combination with separation tools such as two-dimensional gel electrophoresis and 
multidimensional liquid chromatography, allow for the parallel analysis of hundreds 
of proteins and peptides (Aebersold & Mann 2003). Although powerful, these 
techniques, however, are low throughput and require a high degree of technical skill. 
In particular, they currently lack the sensitivity and dynamic range to detect very low 
abundant proteins in complex biological samples (Sydor & Nock 2003). This is 
especially the case for body fluids such as serum, plasma which are exceptionally 
difficult to analyse due to a dynamic range of more than 10 orders of magnitude in 
concentration that separates the highest and lowest abundant proteins (Liotta et al. 
2003).  
 
Limitations of existing proteomic technologies have consequently driven the 
development of novel tools for the investigation of proteomes. An emerging 
technology is the protein microarray (Kodadek 2001; Templin et al. 2002; Wilson & 
Nock 2003; Zhu & Snyder 2001) which is developed using the concept of the current 
DNA microarray for mRNA expression profiling (Schena et al. 1995), but to profile 
protein expression (Templin et al. 2004). However, the biochemical diversity, and the 
sheer number of proteins are such that an equivalent analysis is much more complex 
and thus difficult to accomplish. Instead, low density antigen and antibody 
microarrays can be used as a high-throughput multiplex screening tool to measure 
specific target proteins associated with a disease process or therapeutic intervention 
(MacBeath 2002). They have a wide range of potential applications, especially in the 
drug development process. Antibody microarrays could potentially revolutionize the 
area of biomarker discovery, validation and monitoring of markers of disease onset 
and progression, drug efficacy and toxicity (Kodadek 2001). Most importantly, 
protein microarrays have the advantage of scalability, being amenable to automation, 
multiplexing as well as low sample volume requirements while giving a high degree 
of sensitivity and broad dynamic range. 
 
This introduction is in two parts. The first part provides an overview of the protein 
microarray concept, the current strategies used to generate protein microarrays, and 
the technical aspects. The challenges and shortcomings of these approaches, as well as 
the potential applications of protein microarrays will be discussed. The second part 
   2 
provides and overview of the pathogenic complexity of rheumatoid arthritis. 
Rheumatoid arthritis in this thesis was chosen as a disease model for proof of concept 
to demonstrate the feasibility of a microarray platform for monitoring the expression 
levels of selected proteins described to be associated with RA. 
 
1.1 Protein microarray technology and concept 
The protein microarray is based on the technology of coupling the capture molecules, 
either antibodies, proteins, antigens or ligands, down onto a support in an array format 
for multiplexed analysis (Haab, Dunham, & Brown 2001; MacBeath 2002; Zhu & 
Snyder 2003). As the concept is, that each of the capture molecule-protein analyte 
pairs is mutually exclusive, that is, each capture molecule only binds to a single 
cognate protein analyte and vice versa, a single microarray comprising multiple 
capture molecules can be used to assay the presence of different protein analytes in a 
complex mixture. There are two major technologies that are being utilized for 
multiplex measurement: spot-based arrays, and bead-based fluidic arrays. An example 
of the fabrication of these two technology platforms using antibodies as the capture 
agents is shown in Figure 1. 
 
Spot-based arrays are primarily produced by direct printing of capture molecules onto 
the planar support surfaces (Huang 2001; Moody et al. 2001; Wiese et al. 2001). 
Planar surfaces involve glass slides which can be treated with numerous chemistries 
to improve binding capacity, plastic plates and membranes (Huang 2003). Deposition 
of subnanolitre volume of capture molecule solution is achieved by printing 
technologies. Detection of captured protein is usually accomplished by fluorescence 
or chemiluminescent system. Imaging in these cases is accomplished with a CCD 
camera or laser scanner (Seong & Choi 2003). Bead-based fluidic arrays utilize beads 
with colour and/or size differentiation of which capture molecules are conjugated to. 
Captured molecules on the beads are detected by fluorescence labelling and the signal 
is analyzed by flow cytometry (Bellisario, Colinas, & Pass 2001; Dunbar et al. 2003). 
This chapter will primarily focus on spot-based array technology. 
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Figure 1: Different types of microarrays, either planar microarrays or bead-based 
microarrays can be employed for multiplexed microarrays. The figure was taken from 
(Templin et al. 2004). 
 
1.1.1 Assays on a microspot: fundamental principles of spot-based arrays 
The ability to miniaturize microarrays is of fundamental importance, especially with 
regard to assay sensitivity and sample amount needed. The basic principles of 
miniaturizing microarray assays were described by Ekins and coworkers (Ekins 1989; 
Ekins 1998). This theory demonstrates that the analysis of the same amount of capture 
agent in a small area is more sensitive than in a larger area (Figure 2). The sensitivity 
of the system is increased because the binding reaction occurs at the highest possible 
concentration, and the capture-detection complex is localized in the microarray spot. 
This occurs because the target molecule is not the limiting factor in a small spot. 
Signal intensity will remain virtually constant below a certain spot size (Ekins 1989), 
even if there is a further reduction in spot size. As the spot size increases, for a given 
amount of capture agent, the signal intensity subsequently decreases (Espina et al. 
2003). 
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Figure 2: As the arrayed spot size increases for a given analyte concentration, the 
density of the spot reaches a maximum. In other words, for a given concentration of 
analyte occupying increasing spot diameters, the intensity (density) of the spot will 
decrease as the spot diameter increases. This is due to the same number of target 
molecules occupying an increasingly larger area. In contrast, as the spot size 
decreases, the density increases for a decreasing concentration of analyte. There is a 
point at which the spot intensity will remain constant for decreasing spot size. 
Incorporation of a sample dilution curve into the printed array format permits the 
analysis of each analyte in its linear dynamic range without limitations due to the 
unmatched antibody association/ dissociation constants. This figure was adapted from 
(Stoll et al. 2002). 
 
1.1.2 Types of spot-based array formats 
Depending on the desired application, different microarray designs can be 
constructed. Currently there are two types of protein microarray set-ups which have 
been defined: reverse phase arrays (RPAs) and forward phase arrays (FPAs) (Liotta et 
al. 2003) (Figure 3). 
 
In RPAs a small amount of a tissue or cell sample is immobilized on each array spot, 
such that an array is composed of different patient samples or cellular lysates (Espina 
et al. 2003; Paweletz et al. 2001; Petricoin et al. 2002). In the RPA format, each array 
is incubated with one detection protein (e.g., antibody), and a single analyte endpoint 
is measured and directly compared across multiple samples (Figure 3).  
 
In FPAs, capture agents, usually an antibody or protein antigen, are immobilized onto 
the surface and act as a capture molecule. Each spot contains one type of immobilized 
antibody or capture protein. Each array is incubated with one test sample, and 
multiple analytes are measured at once (Figure 3).  
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Figure 3: Types of protein microarray platforms. Forward phase arrays (top) 
immobilize a capture molecule such as an antibody designed to capture specific 
analytes with a mixture of test sample proteins. The bound analytes are detected by a 
second sandwich antibody or by labeling the analyte directly (upper right). Reverse 
phase arrays immobilize the test sample analytes on the solid phase. An analyte-
specific ligand (e.g., antibody; lower left) is applied in solution phase. Bound 
antibodies are detected by secondary tagging and signal amplification (lower right). 
The figure was taken from (Liotta et al. 2003). 
 
Antibody microarray is one form of FPAs. Antibody microarrays are usually 
produced in two forms, either by a sandwich assay or by direct labelling approach 
(Zhou et al. 2004). The sandwich assay approach to antibody arrays is simply a 
multiplexed version of standard ELISA immunoassays. This approach utilizes a 
matched pair of antibodies specific for every protein. One antibody is immobilized on 
a solid support and captures its target molecule from the sample. Using the 
appropriate detection system, the labelled second antibody detects the bound targets. 
The main advantage of the sandwich assay is its high specificity, accuracy and 
sensitivity (Templin et al. 2004). High sensitivity is achieved by a dramatic reduction 
of background yielding a high signal-to-noise ratio. This is primarily due to the high 
specificity accomplished through the combination of two analyte-specific antibodies 
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(Maiolini & Masseyeff 1975). Quantitative information of the abundance of proteins 
can also be derived from the sandwich assay approach (Huang et al. 2001; Schweitzer 
et al. 2002). The main drawback of this approach is the requirement for a pair of 
validated antibodies to be available for each analyte being analysed, therefore, 
limiting the scalability of this format. 
 
As an alternative to the sandwich assay, protein-containing samples can be labelled 
with fluorescent tags followed by direct detection after capture. Other haptens such as 
radioactive isotope can also be used as label, followed by detection with an anti-
hapten antibody conjugated to a fluorescent dye or to an enzyme such as horse-radish 
peroxidase (Zhou et al. 2004). An adaptation of the direct labelling approach was 
described by Haab and co-workers (Haab, Dunham, & Brown 2001) (Figure 4). In 
their approach, proteins from two different biological samples are labelled with either 
Cy3 or Cy5 fluorophores. These two labelled samples are then equally mixed together 
and applied to an antibody microarray. In this case, one compares the relative 
fluorescence intensity at each antibody feature so as to identify differences in protein 
levels between the two samples, for example treated vs. untreated or diseased vs. 
healthy. This approach has successfully been used to study cancer markers (Miller et 
al. 2003) and to protein profiling in cancer tissues (Knezevic et al. 2001). 
 
The main advantages of direct label arrays are that detection antibodies are not 
necessary and incubation time of the assay procedure is relatively short (Li, Nath, & 
Reichert 2003). A major limitation to this approach is the poor signal-to-noise ratio 
often obtained, meaning that the sensitivity is generally not very high. Since 
potentially all proteins in a sample are labelled, proteins typically present in high 
amounts such as albumin in serum can non-specifically bind or adsorb to the 
antibodies or to the microarray surface leading to the measurable interference (Haab 
2003). The background binding would subsequently reduce detection sensitivity or 
data accuracy. In addition direct labelling procedures can reduce the solubility and 
structural integrity of the analysed proteins (Phelan & Nock 2003) and labelling 
efficiency is often variable which would then compromise reproducibility (Phelan & 
Nock 2003). Another problem with this approach is that it does not quantify the 
protein antigens, but merely states relative abundance between samples. 
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Figure 4: Comparative expression analysis using direct labelling. Molecules from 
controls and samples are isolated and labelled with two different fluorophores. Equal 
amounts of the samples are mixed and incubated simultaneously on the capture 
microarray. Labelled target molecules bound to their immobilized capture molecules 
are detected using dual colour modes. The signal intensities between the control and 
test samples are quantitatively compared and expression differences identified. The 
figure adapted from (Templin et al. 2004). 
 
1.2 Protein microarray development: critical factors and challenges in spot-based 
arrays  
In the development of protein microarrays many critical factors and analytical 
challenges are encountered. One of the most critical factors is the careful selection of 
capture molecules to avoid cross-reactivity. The capture molecule in the multiplex 
array must specifically recognize a single protein in a complex mixture and not cross-
react with any others, this is referred to as specificity (Phelan & Nock 2003; Templin 
et al. 2003; Zhu & Snyder 2003). Another major challenge concerns the wide range of 
analyte concentration to be detected. Proteins of interest may exist in a broad dynamic 
range (up to a concentration of factor 1010) (Espina et al. 2003), especially in body 
fluids. Consequently, the assay may need to simultaneously detect proteins present at 
very different concentrations on a single array. It is, therefore, important to identify 
capture agents which are highly specific for the protein of interest, with an affinity 
sufficient to effectively capture proteins at various concentrations (Phelan & Nock 
2003). Another critical factor involves the immobilization of capture agents onto the 
solid support. It is crucial that capture agent are stable and remain in a functional state 
once immobilised. Among the other technical factors which are critical for the 
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successful development of protein microarray, there are the solid supports and 
chemical surfaces, printing methods, assay matrix, signal generated and signal 
detection (Haab, Dunham, & Brown 2001; Huang 2003; Templin et al. 2003; Zhu & 
Snyder 2003). These will be discussed in more detail in the following sections. 
 
1.2.1 Capture agents 
A capture agent is referred to as the molecule which is immobilized onto a microarray 
solid support and which is specific for a target molecule (Phelan & Nock 2003). 
Different types of molecules can serve as possible capture agents, and these are 
summarized in Table 1. 
 
Table 1: Classes of capture molecules.  
Capture molecule Reviewed in 
mAb (Goldman 2000; Kohler & Milstein 1975) 
Polyclonal sera (Valle & Jendoubi 2003; Zhang 2003) 
Antibody fragments 
(scFv/Fab) 
(Gao et al. 1999; Knappik et al. 2000) 
Aptamers 
(DNA/RNA/peptide) 
(Brody & Gold 2000) 
mAb - monoclonal antibody 
Fab - antigen-binding fragment 
scFv - single-chain variable region fragment 
 
Highly specific capture molecules which exhibit high affinity to their target molecules 
are a prerequisite for the establishment of protein microarrays used for the 
identification and quantification of target proteins. Antibodies are particularly well 
suited to the task of protein profiling on a microarray, and represent the most common 
capture agents used for protein profiling microarrays (Huang 2003). Highly specific 
monoclonal antibodies can be generated by mouse immunization and continuous 
culture of hybridoma cells (Goding 1980). Importantly, this represents a potentially 
unlimited supply of uniform and pure binding molecules. Polyclonal antibodies, on 
the other hand usually contain multiple epitope specificities and are limited in 
quantity to the amount of serum that can be obtained from the immunized animal. 
Moreover, their performance in a protein microarray format may be impaired by a 
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decreased density of specific binding sites due to the presence of antibodies that do 
not recognize the protein of interest. Thus, monoclonal antibodies are preferred as 
capture agents for microarray fabrication. However, due to the lengthy, labour-
intensive and thus expensive nature of monoclonal antibody production efforts have 
been undertaken to develop alternative technologies (Phelan & Nock 2003). One 
attractive approach is to use phage display techniques combined with highly diverse 
synthetic libraries. These libraries can be used to isolate antibody fragments against 
target proteins in a significantly shorter time frame than it is possible with 
immunization-based methods (Li 2000). Phage-display libraries of antibody 
fragments, therefore, offer the potential for antibody production in a large scale.  
 
A major challenge encountered with the development of protein microarrays is the 
requirement for high affinity capture agents. Capture agents need to exhibit an affinity 
to the target molecule which is relevant to effectively capture target molecules. The 
binding of protein to capture molecule can be quantified by dissociation rate constant 
(Kd) (Wild 2001). The dissociation constant of monoclonal antibodies for their 
cognate proteins varies from 10-7 to 10-12 M. These values often define the lower limit 
of assay detection, thus detection sensitivity increases with the decreased Kd for 
capture antibody (Varnum, Woodbury, & Zangar 2004). For protein microarrays the 
dissociation constant for a useful antibody is generally at least in the single-digit 
nanomolar range (Wilson, Phelan, & Nock 2005). Lower affinities are usually 
associated with rapid (>10-3M/sec) dissociation rates and a loss of  antibody- antigen 
complexes during the wash and incubation steps (Wilson, Phelan, & Nock 2005).  
 
For accurate quantitative measurements a relationship must be obtained between 
signal intensity and analyte concentration (Wild 2001). The affinity constants, 
however, constrain the range of the assay (Wild 2001). The detection range can only 
be attained if the concentration of the protein analyte and antibody are properly 
matched to the affinity. That is why it is important to select the capture and detection 
antibodies with the affinities adequate to measure the required concentrations of each 
analyte of interest belonging to the multiplexed array.  
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1.2.2 Solid support and surface chemistry 
Protein microarrays may be fabricated on glass and plastic slides treated with various 
surface chemistries, plates or membranes. An optimal solid support or surface 
chemistry for protein microarrays should have the following characteristics: high 
binding capacity, preservation of capture agent functionality after immobilization, 
ease of manufacture, high reproducibility, high signal-to-noise ratio, and reasonably 
easy to manipulate (Kumble 2003). 
 
An important issue during the microarray preparation is that the capture agent remains 
in a functional state once immobilized onto a solid surface. For maintaining functional 
integrity, buffers with similar properties to the physiological fluid are typically used 
for the preparation of capture agents solutions prior to spotting. For instance, the 
addition of stabilizers such as (30-40%) glycerol (MacBeath & Schreiber 2000; Zhu 
& Snyder 2003) can help maintain the native properties of antibodies. It is also 
advantageous to have the antibodies in a solution with the physical characteristics 
similar to physiological properties, (e.g., viscosity), to ensure uniformity between the 
different antibody spots. 
 
A wide variety of surface substrates and attachment chemistries have been evaluated 
for the immobilization of capture agents on protein microarrays. Hydrophobic plastics 
such as polystyrene are commonly used surfaces. Most proteins physically adsorb 
onto polystyrene surfaces by van der Waals, hydrophobic and electrostatic 
interactions (Espina et al. 2004). This type of physical adsorption is generally used to 
immobilize antibodies onto polystyrene 96-well plates (Moody et al. 2001). The 
advantage of this type of immobilization is that it is relatively simple to perform, since 
it does not require any modifications of the protein for its attachment to the surface. 
The disadvantage is that the immobilized proteins often becomes denatured due to 
multiple uncontrolled interactions between the protein and the surface material 
(Morozov 2005). The physical adsorption of proteins onto surfaces also tends to be 
heterogeneous, with proteins clustering together in patches (Sydor & Nock 2003). 
Adsorption of proteins onto surfaces can also lead to problems with protein desorption 
during the assay, which can lead to signal loss. Similar effects are observed on other 
surfaces used for non-covalent protein adsorption, such as poly-lysine coated glass 
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which is hydrophilic and positively charged (Haab, Dunham, & Brown 2001) or 
hydrophobic nitrocellulose. 
 
An alternative method for attachment of protein to surfaces is by covalent binding via 
amines or other amino acid side chains on chemically coated surfaces, such as 
aldehyde (Angenendt et al. 2002; MacBeath & Schreiber 2000; Peluso et al. 2003). 
The advantage of covalent binding is its stability, and the capture agents are 
immobilized at very high densities (Lahiri et al. 1999). This directly translates to 
highly sensitive detection. A drawback, however, is the possibility of protein 
denaturation. 
 
Both adsorption and covalent binding approaches, however, attach proteins to the 
surface in a random fashion. As a consequence, this may alter the native conformation 
of proteins, reduce the activity of proteins or make them inaccessible to the binding 
agent (Zhu & Snyder 2003). An alternative approach is the utilization of site-oriented 
immobilization methodologies (Templin et al. 2002; Zhu et al. 2000). Nock et al. 
(Peluso et al. 2003) found that 90% of Fab' fragments attached to a streptavidin-
coated surface through biotinylation of the thiol group of antibody Fab' fragment are 
active, while randomly attached Fabs have up to sixfold lower activity. The benefit of 
orienting full-length antibodies is, however, by far not as pronounced. This is 
reflected in the fact that a wide variety of substrates have been used successfully for 
antibody microarray applications (Nielsen & Geierstanger 2004). The disadvantage of 
the oriented immobilization is the possible loss of the capture agent functionality. 
 
1.2.3 Arraying devices for immobilisation of capture agents  
One of the main technical challenges of microarray measurements is the production of 
the microarray themselves. In order to carry out reproducible and reliable assays on a 
protein microarray, it is necessary to print the capture agent in a way that results in 
efficient deposition of functional capture agent. Commercially available array 
printers, providing different types of printing methods, can be used for the printing of 
micrroarrays in a variety of configurations (Schena 2000). Each printing method has 
its advantages and disadvantages depending on the type of sample to be printed, 
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sample volume and microarray density. Printing technologies currently exist in two 
forms: contact and non-contact arrayers.  
 
1.2.3.1 Contact printing devices  
Contact printing is accomplished by direct contact between a metal pin head and the 
solid surface. Contact printing devices come in three main formats, solid pin, quill, 
and pin and ring.  
 
A solid pin printing assembly is composed of a solid pin with a flat end. Submerging 
the pin in a liquid sample transfers a sub-nanolitre volume of sample to the tip of the 
pin. Direct contact of the pin with the surface delivers the fluid to the surface. The pin 
diameter and fluid properties determine the volume of fluid deposited, and thus the 
spot size. The solid pin format does not lend itself to duplicate or triplicate printing 
due to the necessity of the pin to be re-submerged in the sample for each spot printing 
(Espina et al. 2003; Schena 2000). 
 
A quill type printing assembly consists of a flat pin head with a defined hollow bore, 
similar to quill-style writing instruments. Sample fluid wicks into the hollow space 
and is deposited on the solid surface when the pin head touches the surface. The quill 
style formats allow multiple spot printing from each sample (Schena 2000). 
 
Pin and ring assemblies are a combination of a ring that holds microliter quantities of 
sample and a flat head pin. The pin travels through the fluid retained in the ring and 
deposits the sample on the solid surface. The pin and ring assembly is capable of 
replicate spot printing (Schena 2000).  
 
The dispensed volume of printing solution during the contact printing process ranges 
from 0.3-2 nL per drop (Espina et al. 2003). The main disadvantage of contact 
printing is the danger that proteins might by denatured while the pin touches the 
surface. The protein can also be deactivated or lose its functionality because of direct 
contact with the metal pin during printing. Moreover, proteins might remain attached 
to the pin heads following washing leading to cross-contamination of samples. Lastly 
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contact printing might result in less homogenous protein spotting causing assay 
variability. 
 
1.2.3.2 Non-contact printing devices 
Non-contact printing devices utilize a sensor for depositing printing solution (Espina 
et al. 2003) above the surface. This sensor may be either a piezoelectric crystal or a 
solenoid.  
  
Piezoelectric devices consist of a glass capillary tube surrounded by a deformable 
piezoelectric material (Espina et al. 2003; Schena 2000). Piezoelectric material is 
typically a ceramic that changes form in the presence of an electrical charge. The 
deformation induced by electric charge of the piezoelectric material provides pressure 
on the glass capillary containing the sample, causing fluid to be dispensed from the tip 
of the glass capillary. Picoliter quantities of fluid may be dispensed with a 
piezoelectric tip. Typical sample delivery volumes for these devices are 0.1–0.3 nL.  
 
Syringe solenoid systems utilize pressure supplied by a syringe to aspirate  fluid into a 
sample tip. Opening the solenoid valve allows droplets of fluid to be ejected from the 
tip. The dispensed droplet volume is 4–8 nL (Schena 2000).  
 
Non contact printing is generally believed to yield the lowest spot to spot variability 
in the amount of sample deposited. In addition, non contact printing could cause less 
harm to the protein structure because the capillary does not touch the surface, but the 
shear forces produced during droplet delivery may have a negative effect on protein 
structure (Morozov 2005).  
 
1.2.4 Signal generation and signal detection 
The binding between capture molecule and protein analyte can be monitored by 
quantifying the signal generated from each pair using various detection techniques 
(MacBeath 2002; Zhu & Snyder 2003). Detection of captured protein is usually 
accomplished by fluorescence or chemiluminescent labeling (Espina et al. 2004). 
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In chemiluminescence detection, the signal is generated with secondary antibodies 
conjugated for instance to alkaline phosphatase or horseradish peroxidase. The 
enzymatic oxidation of a substrate, such as luminol, produces a prolonged emission of 
light, which is captured with phosphor imager or a CCD camera. The sensitivity of 
chemiluminescence can also be increased by performing the oxidation of luminol by 
horseradish peroxidase in the presence of chemical enhancers such as phenols. This 
has the effect of enhancing the light output by approximately 1000-fold and extending 
the time of light emission, consequently increasing the sensitivity. 
Chemiluminescence detection has been used to detect proteins on membranes (Joos et 
al. 2000), glass arrays (Arenkov et al. 2000) and 96-well plates (Mendoza et al. 1999; 
Moody et al. 2001). Chemiluminescence, although highly sensitive, has drawbacks in 
terms of the potential for low feature resolution due to signal bleeding and limited 
dynamic range. 
 
Fluorescence is the most commonly used method to detect proteins on microarray 
formats (Templin et al. 2002). This popularity is mainly for reasons of simplicity, 
stability and availability of fluorescent scanners tailored for microarray use. 
Fluorescent molecules absorb photons of light energy from an external light source. 
This causes an excitation of electrons within the molecule and an emission of light at 
a different wavelength than the incident light. The Cy3 and Cy5 fluorescent dyes are 
commonly used for fluorescent detection, and have been widely utilized in DNA 
microarray applications (Kumble 2003). Fluorescence can be directly labeled onto 
proteins (Haab, Dunham, & Brown 2001) or conjugated onto other detection molecule 
such as streptavidin. Since there is low auto-fluorescence in glass slides, protein 
arrays are normally constructed on glass when using fluorescence detection. However, 
the sensitivity of fluorescence detection is usually lower than chemiluminescence, and 
may be insufficient in some cases to measure proteins present at very low 
concentrations.  
 
To address this limitation, a powerful signal-enhancement methods (e.g. rolling 
circles amplification (RCA) (Schweitzer et al. 2002) and thyramide signal 
amplification (TSA) (Woodbury, Varnum, & Zangar 2002)) have been developed. In 
RCA, an oligonucleotide-conjugated antibody binds to a hapten (such as biotin) 
common on all antigen-specific secondary antibodies. A circular DNA molecule then 
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hybridizes to the oligonucleotide and replicates using DNA polymerase, thereby 
amplifying the signal. Tyramide signal amplification (TSA) uses horseradish 
peroxidase (HRP) to catalyze biotin accumulation from biotinyl–tyramide, an HRP 
substrate. The "amplified" biotin localized at the reaction site can be detected using 
strepatvidin-HRP in conjunction with an HRP substrate that produces a fluorescent or 
chemiluminescent product. 
 
The binding to capture agents of protein analytes in a sample is detected by scanning 
the array, using either a scanning confocal laser or a charged coupled device (CCD) 
camera-based reader (Seong & Choi 2003). Once the array image has been generated, 
sophisticated software is used to obtain signal intensity values for each of the spots 
after gridding the elements of the array.  
 
1.2.5 Matrix to prepare calibrators for protein expression microarrays 
As in any other immunoassay, standards curves are required for the quantitative 
application of protein expression microarrays. Standard curves are used to calculate 
the concentration of analytes in the measured samples. Calibrators can be prepared 
using different matrix: e.g. serum, plasma, culture medium or buffer. According to the 
Food and Drug Administration (FDA) guidance for pharmacokinetic assays (Food and 
Drug Administration 2001) (Findlay et al. 2000), calibrators should be prepared 
preferentially in the same matrix as the tested samples. However, using the same 
matrix can complicate assay development and validation. This is because of the 
presence of the endogenous molecules of interest. As a consequence the blank 
calibrators can not be generated which perturb the production of the quantitative 
standard curves. In addition, other molecules such as soluble receptors, anti-cytokine 
antibodies, autoantibodies or heterophilic antibodies present in the matrix can 
potentially interfere with the measurements (Hennig et al. 2000). As a consequence, 
one of the strategies that can be used to limit or eliminate interference from 
endogenous molecules involves preparing the calibrators in a heterologuos biological 
matrix (e.g. biological matrix of another species) that is lacking the measured human 
analytes (Findlay et al. 2000). However, heterologuos matrix for standard curve 
generation still needs to be verified for the presence or absence of any cross reactivity 
between the heterologuos matrix and assay regents. Another strategy is to prepare a 
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standard curve in an analyte free protein based buffer (Findlay et al. 2000). 
Nevertheless this approach could also provide the false measurements as for instance 
functionality of some proteins depends on the presence of other naturally occurring 
matrix components e.g. protein (Zhu & Snyder 2003).  
 
1.3 Application of protein microarrays 
Protein microarrays can be classified into two major categories according to their 
applications. These are defined as protein expression microarrays, and protein 
function microarrays (Kodadek 2001). Protein expression microarrays mainly serve as 
an analytic tool, and are used to detect and quantify proteins, antigens or antibodies in 
a biological fluid. Protein function microarrays on the other hand are used to study 
protein activities such as protein-protein, enzyme-substrate and small molecule-
protein interactions. (Huang 2003). Depending on the microarray type, different 
capture agents are immobilized onto the microarray surface. The different protein 
microarray applications are shown in Figure 5, and are described in the following 
sections. 
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Figure 5: Applications of protein microarrays. Figure adapted from (Zhu & Snyder 
2003) 
 
 
1.3.1 Protein expression microarrays 
Protein expression microarrays involve the profiling of protein levels in a complex 
mixture. For instance, they can be used to screen samples for the presence of 
antibodies or antigens associated with a disease state. The examples of protein 
expression microarrays to measure antibodies are described below. 
 
Miniaturized and multiplexed immunoassays were described for the use to screen sera 
for the presence or absence of a large number of different types of autoantibodies 
(Joos et al. 2000; Robinson et al. 2002). Autoantigens used as diagnostic markers for 
autoimmune diseases were immobilized in a microarray format. Consequently, 
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different types of autoantibodies could be accurately determined from patient serum 
(Joos et al. 2000). This reflects the enormous potential of protein microarrays for 
investigating the humoral response against a large number of antigens.  
 
Allergy diagnostics might find protein microarrays quite a suitable format as a 
sufficiently high number of parameters must be determined. In general, allergies are 
being diagnosed by provocation testing and employing IgE serology which makes use 
of allergen extracts or complex mixtures of different potential allergens (Harwanegg 
et al. 2003). The identification of the disease-causing allergenic molecules is a costly 
and time consuming procedure. Miniaturized and multiplexed ligand-binding assays 
can avoid most of the current limitations. Hiller et al. (Hiller et al. 2002) used 78 
recombinant and 16 purified allergen molecules to generate a microarray. The 
individual IgE reactivity towards the microarrayed allergenic components reflected 
the clinical sensitivity of the individual patients to the different allergens.  
 
1.3.2 Protein function microarrays 
Functional protein microarrays are constructed by immobilizing large numbers of 
purified proteins onto a solid surface. Protein function microarrays have the potential 
in assaying for a wide range of biochemical activities, including protein–protein, 
protein-small molecule and enzyme–substrate interactions. 
 
Many biological events are mediated by protein-protein interactions. By identifying 
protein interaction partners of known function with those whose role is 
uncharacterised, it is often possible to infer the biological process and/or activity of 
the uncharacterised protein. Moreover, novel functional activities in additional to 
those currently identified for known proteins can be uncovered. In protein-protein 
interaction microarrays the recombinant or purified proteins are spotted onto the array 
support. Other purified proteins are then applied to the array and analyzed for their 
interactions. For example, Zhu et al. (Zhu et al. 2001) created a protein microarray 
containing 5,800 recombinant proteins. Using this proteome microarray 39 
calmodulin-interacting proteins were identified by adding biotinylated calmodulin to 
the microarray. Within this set, several expected calmodulin-binding proteins as well 
as 33 novel calmodulin-interacting partners were revealed. 
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 The ability to screen whole proteomes for protein-binding molecules (or drugs) has 
important implications for the drug discovery and development process. For many 
drugs identified by cell-based screening, the mode of action is often unknown. By 
screening a protein array with drugs, candidate protein targets can be determined in a 
single experiment. MacBeath and Schreiber demonstrated the utility of this approach 
for screening labelled ligands for potential binding partners on protein microarrays in 
a high-throughput manner (MacBeath & Schreiber 2000). Specifically, they were able 
to show binding of the FK506 binding protein, FKBP12, with several compounds. 
Alternatively, small molecules that are produced by combinatorial chemistry or 
potential ligands immobilised onto arrays could also be used to identify protein 
targets. 
 
Enzyme-substrate interaction microarrays can be used for the identification of novel 
enzyme activities. Protein kinases, in particular, represent a class of proteins that are 
of great interest for pharmaceutical development. A comprehensive array of kinases 
would have utility for development of new kinase inhibitors as well as for profiling 
the specificity of existing inhibitors. For example, yeast protein kinases (119 of the 
122 known or suspected protein kinases from Sacharomyces cerevisiae) were arrayed 
onto microwell plates and used to characterise substrate specificities with 17 different 
substrates in microwell-type arrays (Zhu et al. 2000). As a result, novel aspects of 
protein kinase selectivity were uncovered. Clearly, the next step is to create a human 
kinase array in a similar manner. 
 
1.4 Protein Microarray for protein biomarker screening  
A protein biomarker is defined as a protein that is objectively measured and evaluated 
as an indicator of normal biologic processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention (Frank & Hargreaves 2003). In clinic, 
biomarkers of efficacy or mode of action, are especially valuable as they can offer 
both sensitive and specific measurable endpoints to better monitor and predict patient 
responses to drug treatment. Toxicity and safety markers are indicators of adverse 
drug effects. Ideally, such biomarkers would act as a warning sign to signal the 
beginning of an adverse drug response at a much earlier timepoint prior to the 
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manifestation of a pathological condition. Another type of biomarker is a surrogate 
marker (a substitute for a clinical endpoint), which is often related to disease 
progression or regression. Biomarkers which are measured in readily accessible body 
fluids are the most valuable for disease detection and treatment monitoring, as only 
non invasive techniques are required for sample collection (Colburn 2003). Therefore, 
efforts at discovering disease markers have concentrated on identifying proteins in 
body fluids, such serum, plasma, urine, synovial fluid, cerebrospinal fluid (CSF), 
saliva and nipple aspirate. 
 
The usual ‘single biomarker’ approach to disease diagnosis and prognosis, is 
undergoing a paradigm shift as it is becoming increasingly clear that single markers 
do not show enough specificity and sensitivity to be applied to all patients due to 
inter-individual variability. Panels of biomarkers, which offer higher sensitivity and 
specificity for disease are proposed for better patient stratification and management in 
clinic (Seong & Choi 2003). 
 
One of the driving forces of the “–omic” technologies in the drug discovery and 
development pipeline is the identification and utilization of sensitive and specific 
biomarkers to advance clinical diagnostics and therapeutic monitoring. These “–omic” 
technologies have led to the discovery of a vast amount of biomarker candidates for 
disease, drug efficacy and toxicity. This situation, however, has created new 
bottlenecks in drug development. Once a biomarker candidate has been defined, a 
statistical validation across many samples has to be performed, and there is an 
immediate need for tools that help to both validate these potential biomarkers and to 
screen them once in clinic (Bodovitz & Joos 2004; Ilyin, Belkowski, & Plata-Salaman 
2004). 
 
Currently, the conventional ELISA, radioimmunoassay and western blotting 
techniques are used for biomarker validation and screening (MacBeath 2002). 
However, ELISA allows for the analysis of one analyte per assay only, thus many 
assays are required for many analytes. Substantial savings could be made both in 
terms of time, cost, sample volume and precious reagents by multiplexing and 
miniaturizing these assays. Moreover, simultaneous measurement of analytes of 
interest would allow more information to be obtained from the same sample volume. 
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This is especially important when the amount of sample is limiting (i.e. in preclinical 
studies or “rare” matrix’s such as CSF and synovial fluid). Therefore, this is an area 
whereby protein microarrays could potentially improve biomarker validation, 
therapeutic monitoring and diagnostics by offering a novel format to perform 
immunoassays in a high-throughput multiplexed fashion (Figure 6) (Cahill 2001; 
Kodadek 2001; Wilson & Nock 2003). 
 
 
 
Figure 6: The use of protein microarrays for the development of drug and diagnostic 
biomarkers. Figure taken from (Wilson & Nock 2003). 
 
 
1.5 Rheumatoid arthritis 
1.5.1 Introduction 
Rheumatoid arthritis (RA) is an inflammatory, autoimmune, systemic disease of 
unknown pathogenesis. Rheumatoid arthritis affects about 1% of the Caucasian 
population in a female to male ratio of 2.5/1 (Lee & Weinblatt 2001). The prevalence 
increases with age, and sex differences diminish in the older age group (Sweeney & 
Firestein 2004).  
 
The main feature of RA is persistent inflammatory synovitis usually involving 
peripheral joints in a symmetrical distribution. The joints typically affected are those 
of the hands, wrists, knees and feet. Synovial inflammation causes pain, warmth, 
swelling, tenderness, stiffness and limitation of motion. The potential of the synovial 
inflammation to cause cartilage destruction, bone erosions and joint deformities is the 
hallmark of the disease (Lee & Weinblatt 2001; Sweeney & Firestein 2004). Extra-
articular involvement is another hallmark of RA, and this can range from rheumatoid 
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nodules occurring most commonly over bony prominences to life-threatening heart 
nodules and vasculitis (Smolen & Steiner 2003). 
 
There is no pathognomonic symptom or sign of RA. Diagnosis is based on the use of  
the following diagnostic criteria recognized by The American Rheumatism 
Association (Arnett et al. 1988): 
1)  morning stiffness in and around joints lasting at least 1 hour before maximal 
 improvement;  
2)  soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician;  
3) swelling (arthritis) of the hand joints; 
4)  symmetric swelling (arthritis);  
5)  rheumatoid nodules;  
6)  elevated levels of serum rheumatoid factor (RF); 
7) radiographic changes in hand and/or wrist joints.  
 
At least 4 of the 7 criteria must be present for a minimum of six weeks before a 
diagnosis of RA can be made. Rheumatoid factor is defined as an IgM and/or IgG 
autoantibody reactive against the Fc region of the IgG molecule (Corper et al. 1997). 
These antibodies have low disease specificity and can be detected in sera from healthy 
individuals, and patients with other autoimmune disorders or chronic infections 
(Williams DG 1998). In recent years, anticyclic citrullinated peptide antibody (anti-
CCP) has been characterized as a novel RA-specific antibody that can be detected 
very early in the disease (Bas et al. 2003). 
  
1.5.2  Etiology of Rheumatoid arthritis 
The etiology of RA is unknown, although it appears that genetic, infectious, 
environmental and hormonal factors are involved in complex, interrelated ways 
(Smith & Haynes 2002).  
 
In genetic studies, RA is strongly linked to the major-histocompatibility-complex 
(MHC) class II antigen HLA-DR genes that participate in antigen presentation to 
CD4+ T cells (Lanchbury 1992). It has been found that approximately 70% of 
Caucasian patients with classic rheumatoid arthritis, compared with 28% of patients 
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with non-rheumatoid arthritis, expressed HLA-DR4. This association with HLA-DR4 
has been demonstrated in most populations studied. Some non Caucasian populations 
exhibit a different association. For instance, RA in the Native American population is 
associated with HLA-DR9 (Stastny 1978).  
 
The greater prevalence of RA among women suggests that sex hormones are 
implicated in the development of the disease. This is further endorsed by the 
observation that pregnancy has improving an effect on RA, and patients with RA are 
more likely to be nulliparous before disease onset when compared with healthy 
patients (Hazes 1991). 
 
It has long been speculated that RA could be triggered by infectious agents. There 
have been a large number of infectious agents implicated in RA, including Epstein–
Barr virus and parvovirus, as well as other agents, including bacteria such as Proteus 
and Mycoplasma, but proof of this is still lacking (Silman & Pearson 2002). The 
immune system may overreact to the infectious agent, and continue to attack the 
infected area even after the infection has been eliminated.  
 
Heat shock proteins (HSPs) are a family of proteins produced by cells of all species in 
response to stress. These proteins have conserved amino acid sequences, that is, there 
is a sequence homology. Certain human HSPs and Mycobacterium tuberculosis HSPs 
have 65 per cent sequence homology (Kaufmann 1990). A potential hypothesis is that 
antibodies and T-cells exist that recognize epitopes shared by the HSP of both the 
infectious agents and host cells, triggering an immunological reaction. This is referred 
to as molecular mimicry. 
 
1.5.3 Pathogenesis of Rheumatoid arthritis 
Normal synovial tissue consists of the synovial lining (comprising of one to three cell 
layers) and the synovial sublining, which merges with the joint capsule (Figure 7a). 
The synovial lining consists of two major cell types: macrophages and fibroblast like 
cells. Usually the synovial sublining is relatively acellular. In the early stages of the 
disease, the most noticeable feature is tissues oedema. Vessel proliferation and new 
vessel formation (angiogenesis) is also observed. Further, synovial lining hyperplasia 
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begins to develop (Figure 7b). As the disease enters a more chronic phase, synovial 
lining hyperplasia extends to a depth of over 10 cells. The cells consist of type A 
(macrophage-like) and also type B (fibroblast-like) synoviocytes. The sublining also 
evolves with the disease progression (Firestein 1991). Most noticeably there is a 
exuberant infiltration with mononuclear cells comprising T-cells (predominantly 
CD4+ helper T-cells), B-cells, macrophages and plasma cells (Figure 7b) (Smolen & 
Steiner 2003). New blood vessel formation continues and both the degree and content 
of the cellular infiltrate changes. Generally, an inflammation process exhibits an 
infiltration similar to that described above. Another feature includes the ability of the 
synovium of RA to become locally invasive at the synovial interface with cartilage 
and bone. This result in the formation of a mass of tissue called pannus (Figure 7b). 
The cells of the pannus produce destructive proteins called matrix metalloproteinases 
(MMPs) that cause joint erosion (Smith & Haynes 2002). 
 
How environmental and genetic factors induce RA is not yet understood. One view is 
that the inflammatory process in the tissue is driven by T cells (Fox 1997). It is often 
assumed that the initiation phase of the disease is marked by localization of an 
arthrotropic agent in the joint followed by antigen presentation and specific T cell 
activation (Firestein 1991). Stimulated T cells would subsequently generate cytokines, 
including IFN-γ, that activate macrophages, other T cells, B-cells (which produce 
rheumatoid factor), and endothelial cells. Activation of the vascular endothelium by 
cytokines induces adhesion molecules and recruits new cells that express the 
appropriate counterreceptors into the joint. The accumulation of T cells would 
ultimately result from nonspecific infiltration of the synovium with cells from the 
blood as well as local proliferation of lymphocytes in the synovium that recognize 
their specific antigen in the context of MHC molecules. 
 
1.5.4 Soluble mediators of inflammation and join damage in RA 
Monocytes, macrophages, fibroblasts, and T cells release numerous cytokines on 
stimulation (Firestein 1991). Cytokines are small soluble proteins that mediate 
intercellular communication between cells involved in immune responses. They affect 
cell division, differentiation, and chemotaxis, as well as proinflammatory or anti-
inflammatory actions. Quantitative analyses suggest that there are few T-cell-derived 
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Figure 7: Schematic and radiographic view of a normal joint (a and c) and its changes 
in rheumatoid arthritis (b and d). This figure is taken from (Smolen & Steiner 2003). 
 
cytokines such as interleukins 2 (IL-2) and 17 (IL-17), and interferon gamma (IFN-γ) 
in the inflamed synovial tissue. However, many other cytokines are also present in 
moderate to high concentrations in RA. Tumour necrosis factor (TNF-) and 
interleukin 1 (IL-1) are both present in large quantities in affected synovial fluid and 
synovial tissue (Lee & Weinblatt 2001) (Figure 8). Both TNF- and interleukin-1 are 
likely to have primary roles in the pathogenesis of rheumatoid arthritis. The serum 
and synovial concentrations of both cytokines are high in patients with active 
rheumatoid arthritis (Saxne et al. 1988). Furthermore, TNF- and interleukin-1 are 
potent stimulators of mesenchymal cells, such as synovial fibroblasts, osteoclasts, and 
chondrocytes, that release tissue-destroying matrix metalloproteinases (Shingu et al. 
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1993). Interleukin-1 and TNF- also inhibit the production of tissue inhibitors of 
metalloproteinases by synovial fibroblasts (Shingu et al. 1993). These dual actions are 
thought to lead to joint damage. TNF and IL-1 seem to function synergistically in 
inducing effector function.  
 
Investigations on animal models have also suggested a central role for TNF- and 
interleukin 1 in the process of synovitis and joint destruction. Addition of exogenous 
interleukin 1 or TNF into experimental models of arthritis induces or exacerbates 
synovitis. Furthermore, mice transgenic for TNF-, and mice with dysregulated TNF- 
production develop arthritis (Keffer et al. 1991; Taylor et al. 1996).  
 
 
Figure 8: Simplified schematic representation of cytokine network in rheumatoid 
arthritis. Black arrows indicate upregulatory effects. Red crosses represent pathways 
blocked by anti-TNF drugs. Figure taken from (Lee & Weinblatt 2001). 
 
A subclass of cytokines and cytokine receptors are thought to exert anti-inflammatory 
activity in the synovium. There are two TNF receptors (p55 and p75), both of which 
occur naturally the soluble form in synovial fluid  (Cope et al. 1992). They inhibit 
TNF- activity by competing with cell-surface receptors for binding. Similarly, the two 
interleukin 1 receptors, IL-1R1 and IL-1R2 also occur in the soluble form in synovial 
fluid. These receptors are capable of binding interleukin 1, thus forming competition 
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for cell-surface receptors (Arend 2002). Additionally, a naturally occurring 
competitive inhibitor for interleukin 1 at the IL-1 receptor (IL-1 receptor antagonist 
[IL-1ra]) is also present in rheumatoid arthritis synovial fluid (Arend 2002). This 
member of the interleukin 1 family binds to IL-1R1 without transducing a signal, thus 
blocking the receptor binding ability of IL-1. 
 
To perform the proof of concept studies described in this thesis, prteins that are 
associated with RA were chosen. They are marked as A, B, C, D, E, F. In addition, the 
inflammatory related protein, serum amyloid A (SAA), was also chosen. 
 
1.5.5 Treatment of Rheumatoid arthritis 
Medical management of RA involves five general approaches. The first is the use of 
aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) and simple 
analgesics to control the symptoms and signs of the local inflammatory process. These 
agents are rapidly effective at stopping signs and symptoms, but they appear to exert 
minimal effect on the progression of the disease. Recently, specific inhibitors of the 
isoform of cyclooxygenase (Cox) that is upregulated at inflammatory sites (Cox-2) 
have been developed. Cox-2-specific inhibitors have been shown to be as effective as 
classic NSAIDs (which inhibit both isoforms of Cox), but cause significantly less 
gastroduodenal ulceration. The second line of therapy involves the use of low-dose 
oral glucocorticoids. Although low-dose glucocorticoids have been widely used to 
suppress signs and symptoms of inflammation, recent evidence suggests that they may 
also retard the development and progression of bone erosions. Intraarticular 
glucocorticoids can often provide transient symptomatic relief when systemic medical 
therapy has failed to resolve inflammation. The third line of agents includes a variety 
of agents such as methotrexate (MTX) that have been classified as the disease-
modifying or slow-acting antirheumatic drugs (DMARDs). These agents appear to 
have the capacity to decrease elevated levels of acute-phase reactants in treated 
patients and, therefore, are thought to modify the inflammatory component of RA and 
reduce its destructive capacity. Recently, combinations of DMARDs have shown 
promise in controlling the signs and symptoms of RA. A fourth group of agents are 
the TNF- neutralizing agents, which have been shown to have a major impact on the 
signs and symptoms of RA. A fifth group of agents are the immunosuppressive and 
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cytotoxic drugs that have been shown to ameliorate the disease process in some 
patients.  
 
The pro-inflammatory role of cytokines, and the involvement of different cell types 
and their surface molecules in the pathogenesis of RA, provides the rationale for the 
development of highly specific therapeutics to target these molecules so called 
biologic DMARDs. Targeting of pro-inflammatory cytokines can be achieved by 
several strategies. First, monoclonal antibodies, soluble receptors, binding proteins or 
receptor antagonists can bind to pro-inflammatory molecules or their receptors and 
interfere with receptor ligation and its consequences. Second, anti-inflammatory 
cytokines, such as IL-1ra, IL-4, IL-10 or IL-13, can antagonize the production or 
action of the pro-inflammatory cytokines. Third, monoclonal antibodies targeted 
against differentiation- or function-associated cell-surface antigens can lead to either 
elimination of the targeted cells or interference with the cell's function. Table 3 shows 
the approved therapies that prevent pro-inflammatory cytokines, in particular TNF-α 
and IL-1, from interacting with their receptors. 
 
Table 2: Approved biological DMARDs and related drug development. 
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AIM OF THIS THESIS 
The emerging field of biomarkers is proposed to play a crucial activity in the drug 
development process. Biomarkers have applications in the monitoring of clinical 
responses to therapeutic intervention such as efficacy determination and safety 
monitoring, in the diagnosis, prognosis and monitoring of disease progression, as well 
as in patient population stratification. The drug development plan which makes 
effective use of a biomarker strategy will allow compounds to be developed in a more 
efficient way by reducing drug attrition rates, improving patient management and 
therapy assessment in clinic, and facilitating regulatory decision making. Ultimately, 
biomarkers will provide the possibilities to get safer and more effective drugs to 
market faster. 
 
Recently, proteomic and genomic technologies have dramatically accelerated the 
discovery of a large number of potential biomarkers. Once a biomarker is identified, 
an assay is developed and the biomarker is extensively tested and validated in both 
preclinical and clinical trials. To keep pace with the discovery rate of potential 
biomarkers, high-throughput and/or high-output technologies are needed. Moreover, 
the traditional ‘single biomarker’ approach to disease diagnosis and prognosis, is 
undergoing a paradigm shift as it is becoming increasingly clear that single 
biomarkers do not exhibit enough specificity and sensitivity to be applied to all 
patients because of inter-individual characteristics. Panels of biomarkers are proposed 
for better patient stratification and management in clinic. Therefore, there is also a 
need for the development of screening technologies which would simultaneously 
measure several parameters in a multiplex format. 
 
Enzyme-linked immunosorbent assay (ELISA) and Western Blot have for many years 
been the mainstay techniques in clinical samples analysis. These techniques, however, 
are only suited for the measure of a single analyte per assay. Substantial savings could 
be made in terms of cost, time and sample volume by multiplexing and miniaturizing 
these assays. Subsequently, novel technologies such as protein microarray and flow 
cytometric bead-based assay platforms are currently being developed. These 
technologies allow for: the evaluation of multiple analytes in a single sample; the 
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utilisation of minimal sample volumes to obtain data; and a more rapid evaluation of 
multiple analytes in a single platform. 
 
The aim of this thesis was to examine whether a protein microarray platform can be 
applied to the drug development process for monitoring biomarkers in both preclinical 
and clinical studies. In order to demonstrate the feasibility of this approach, 
rheumatoid arthritis (RA) was chosen as a model for proof of concept. Several 
proteins which were described in the literature to be associated with RA were 
selected, and a protein microarray platform for the simultaneous measurement of 
these proteins in serum samples was subsequently developed. The robustness of this 
protein microarray was then assessed and finally validated with real sample 
measurements in RA patients. 
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2 Materials and methods 
In this chapter general regents, equipment, and software are listed. The specific 
methods are explained in the individual chapters. 
 
2.1 General reagents 
Table 3: General reagents 
Reagents Manufacturer 
PBS buffer 10 X PBS buffer, Roche Diagnostic, Indianapolis, IN, 
USA 
Tween® 20 Fluka Chemie Sarl, Buchs, Switzerland 
Tris Trizma®, Sigma®, Sigma-Aldrich Steinheim, Germany 
SuperBlock™ Pierce Biotechnology, Inc., Rockford, IL, USA 
Albumin bovine 
(fraction V) 
Sigma®, Fluka Chemie Sarl, Buchs, Switzerland 
Buchs, Switzerland 
SuperSignal® ELISA 
Femto Maximum 
Sensitivity Substrate 
Pierce Biotechnology, Inc., Rockford, IL, USA 
ImmunoPure® 
Streptavidin, 
Horseradish Peroxidase 
Conjugated 
Pierce Biotechnology, Inc., Rockford, IL, USA 
 
Table 4: Buffers 
Buffer Buffer Content 
Wash buffer PBS 1X containing 0.05% Tween 
Assay buffer PBS 1X containing 0.05% Tween, 3% BSA 
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2.2 Software 
 
Table 5: Sofware 
Software Manufacturer 
Quantity One Version 4.2.1 Bio-Rad, Hercules, CA, USA 
Aida Version 5.0 Raytest GmbH, D 75339 Straubenhardt, Germany 
ImaGene™ Version 5.0 BioDiscovery, Inc, El Segundo, CA, USA 
Array Vision™ Version 8.0 Imaging Research Inc., Ontario, Canada 
SOFTmax® PRO 
 Version 3.1.1 
Molecular Devices Corp., Sunnyvale, CA, USA 
 
2.3 Laboratory equipment 
Black plate  Maxisorp™ 96-well plate (Nalge Nunc International,  
   Rochester, NY, USA). 
Transparent plate Maxisorp™ 96-well plate (Nalge Nunc International,  
   Rochester, NY, USA). 
Plate’s shaker  Wesbart (IS89), Fischer scientific, Wohlen, Switzerland  
Washer  Embla, Molecular Devices, Bucher Biotec AG, Basel,  
   Switzerland 
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3 Development of a protein microarray in a glass chip format 
3.1 Introduction 
The protein microarray development process utilises a combination of technologies 
for protein deposition, assay generation procedures, signal detection and data analysis. 
Many attempts have been undertaken to develop protein microarrays using different 
supports, liquid handling and detection systems (Kodadek 2001; Stoll et al. 2002; 
Templin et al. 2003). 
In this chapter the development of a sandwich protein microarray on a glass chip is 
described. The development covered the following steps: 
• comparison of the treatment of a glass chip with two surface chemistries: 
Poly-L-lysine versus self-assembled monolayer of octadecyl phosphoric acid 
ester  
• comparison of contact and non contact piezoelectric arrayers for antibody 
deposition. 
• comparison of different concentration of coating antibodies 
• comparison of different detection systems: CCD camera versus fluorescent 
scanner. 
The results were described in the article: “Development of protein microarray 
technology to monitor biomarkers of rheumatoid arthritis disease”, published in “Cell 
Biology and Toxicology” 2003; 19: 189 – 202 journal. This publication is included in 
the next chapter. 
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3.2  Development of protein microarray technology  
 to monitor biomarkers of  rheumatoid arthritis  
 disease. 
 
 (Cell Biology and Toxicology. 2003; 19: 189 – 202.) 
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3.3 Assay optimization 
In addition to the results of the protein microarray development on glass slide 
described in the previous chapter, additional investigations were undertaken to further 
optimize the assay. The goal was to explore whether adding glycerol to the coating 
solution could potentially help to stabilize the monoclonal antibody used as capture 
agent. In addition glycerol and its viscous properties could help to keep the spots more 
compact, consequently making image analysis more precise, and reducing spot to spot 
variability.  The influence of adding glycerol to a printing buffer was investigated on 
the MCP-1 assay. Antibodies against MCP-1 were diluted in PBS alone and in PBS 
with the addition of 10, 20, 30, 40 and 50% of glycerol. Signal generated during 
sandwich assay for the concentration of 5 ng/mL of MCP-1 was plotted against 
different amounts of glycerol added to a coating solution (Figure 9). The results 
showed that the signal intensity decreased when 10% of glycerol was added to a 
coating solution. Whereas with the addition of 20-50% of glycerol the generated 
signals was comparable to PBS alone. However the variability between the spots 
(n=16) increased considerably.  
The main concern however, was the difficulty associated with printing coating 
solution containing glycerol. The tips easily became clogged preventing the proper 
dispensing of coating solution. On the base of these findings no glycerol was added to 
the coating solution.  
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Figure 9: Addition of glycerol into a coating solution for MCP-1 assay.  
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4 Development of a protein microarray in 96-well plate format 
4.1 Introduction 
In chapter 3.2, the protein microarray was developed on a glass surface. For 
development, a number of components were evaluated, including the surface 
chemistry for glass treatment, the concentration of coating antibody, the arrayer for 
antibody deposition, and the detection system. Based on the obtained results, the 
following conditions were chosen for the preparation of the microarray: SAM of ODP 
for glass treatment; deposition of coating antibody at the concentration of 200 µg/mL 
using a non-contact piezoelectric printer, and signal detection by fluorescent scanner. 
 
However, the time consuming and complicated process of coating the chip with the 
surface chemistry, together with the lack of robotic automation for assay processing, 
low sensitivity and the high inter-chip variability prompted other alternatives to be 
looked at which would provide less complicated and more robust options for protein 
microarray fabrication. Consequently, an attempt was undertaken to develop a similar 
microarray, but instead of using glass slides, the polystyrene surface of a 96-well plate 
was used as the solid support. 
 
Polystyrene plates in a 96-well format are strongly established solid supports used for 
immunoassays, and are widely utilized in the classical ELISA technique (Angenendt 
et al. 2002). The surface chemistry is standardized and optimized for antibody 
binding, and the assay processing step is fully automated. Therefore, the possibility to 
adapt this well characterized technology to the microarray format could offer many 
advantages over other solid supports.  
 
The availability of long neck tips (from PerkinElmer, UK) compatible with the 
Biochip Arrayer (BCA) printing device provided the option of using a 96-well plate as 
the solid support. Importantly, these long neck tips allow the antibodies to be correctly 
spotted onto the bottom of a 96-well plate (Moody et al. 2001). The development 
process of an antibody microarray to measure serum samples in a 96-well format is 
described in this chapter. The development process involved reagent selection, 
printing protocol optimization, matrix investigation, assay protocol establishment, and 
detection system evaluation. 
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4.2 Materials and methods 
4.2.1 General reagents  
• Serum  
 dog serum, human serum, calf serum – (Novartis Pharma, Basel - internal 
 blood  bank)  
 
4.2.2 Instruments 
• Printing instrument  
 Biochip Arrayer (BCA) (PerkinElmer, Boston, MA, USA)  
 Instrument operated with Biochip BCTable Version 3.2 
 Long-neck tip – Part nr. 7402251, PerkinElmer, Boston, MA, USA 
• Cameras  
 LAS 1000 – Fuji, Raytest GmbH, D 75339 Straubenhardt, Germany  
 LAS 3000 – Fuji, Raytest GmbH, D 75339 Straubenhardt, Germany 
 
4.2.3 Printing system set-up 
The microarray was fabricated using the piezoelectric Biochip Arrayer. The 
piezoelectric system was set to 110-200 volts per tip. The distance between the tip and 
bottom of the well was 0.5 mm. The antibodies were dispensed in duplicates with a 1 
mm distance spots in a 4 x 4 array. The layout of the dispensed antibodies is shown in 
the Figure 10. The dispensing process was programmed and operated with the use of 
BCTable software. 
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Figure 10: Layout of the printed antibodies. The antibodies were printed in duplicate. 
Spots are marked with different colours. Each colour corresponds to the specific pair 
of antibodies. 
 
4.2.4 Assay protocol 
Assay development process in a 96-well format utilised a sandwich assay approach. 
The monoclonal capture antibodies were spotted on the bottom of the well with a non-
contact, robotic dispensing instrument – BCA. 100 µL of calibrated standard cocktails 
or samples were pipetted into pre-designated standard wells of a pre-printed 
microplate. The plate was incubated for 2 hr at 25º C with shaking. Following 
incubation, the plate was subjected to a wash step (300 uL, 3 times with wash buffer) 
to remove unbound material, and 100 uL of biotinylated detection antibody cocktail 
was added to each well. The plate was incubated for 2 hr at 25º C, and subsequently 
subjected to a wash step. A 100 uL streptavidin-horseradish peroxidase conjugate 
solution was added, and the plate was incubated for 30 min at 25º C. Following a 
wash step, chemiluminescent substrate (Super Signal ELISA Femto Substrate) was 
added. Generated chemiluminescent signal was digitized my the immediate imaging 
of the entire plate with the CCD camera. Analysis software was utilized to locate and 
quantify each spot and to generate standard curves. Signal intensities of a sample spot 
were compared to signal intensities from the respective calibrated standard curve to 
enable protein quantification. 
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4.3 Results 
4.3.1 Antibody selection 
The reagents used for the antibody 96-well plate development were commercially 
available ELISA antibody match pairs against different epitopes, and corresponding 
antigens. The panel of biomarkers chosen for the microarray development was A, B, 
C, D, E, F and SAA.  
In order to check the applicability of the antibody match pairs in the multiplex format, 
any potential cross-reactivity was first investigated. All capture antibodies were 
spotted onto the bottom of each well and incubated with PBS spiked with a single 
recombinant cytokine (0.64 ng/mL of A, C, D, 0.58 ng/mL of B, 0.8 ng/mL of E and 
0.038 ng/mL of F) and a cocktail of biotinylated antibodies against all antigens. All 
analytes levels that were not spiked in the sample were not detectable. These findings 
allowed to conclude that the selected antibodies match pairs were specific and did not 
cross react with other then analytes of interest target proteins in this microarray 
format.  
 
4.3.2 Reagents condition optimization 
4.3.2.1 Titration of reagents  
The reagents titration included: coating antibody, detection antibody and streptavidin-
HRP concentration. 
 
In order to select the concentration of coating antibody that would produce the most 
optimal signal-to-noise ratio, antibodies against A, C and D were diluted in PBS to 
four different concentrations: 25, 50, 100 and 200 µg/mL and printed in the bottom of 
each well. Other reagents concentrations were set to the standard conditions 
recommended by the manufacturer: biotinylated Ab – 500 ng/mL; streptavidin-HRP – 
0.2 µg/mL. After performing the assay, signal generated for each analyte was divided 
by the background value. Background was quantified from the well where no analyte 
was added (blank). The signal-to-noise ratio was calculated for the concentration of 
10000, 1000 and 100 pg/mL for each analyte. In the Figure 11 the signal-to-noise 
ratio for the analyte concentration of 100 pg/mL is shown. For A a signal-to-noise 
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ratio of 1.5, 19.5, 92.9 and 129.2 was measured for 10, 50, 100 and 200 µg/mL of the 
concentration of coating antibody. For C - 1.0, 106.9, 113.9, 116.5 and for D - 2.1, 
59.7, 155.1, 157.8, respectively. (Figure 11). The highest signal-to-noise ratio for all 
analytes was obtained when the concentration of 200µg/mL of coating antibody was 
used, as a result this concentration was chosen for microarray fabrication. 
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Figure 11: Coating antibody titration. Different concentrations of coating antibody 
against A, C and D were printed. The best signal-to-noise ratios were obtained using 
coating antibody concentrations of 200µg/mL for all the measured analytes.  
 
Different concentrations of detection antibody were also tested in order to select the 
concentration which gave the optimal signal-to-noise ratio. Capture antibodies against 
A, C and D were printed at the concentration of 200 µg/mL. Respective biotinylated 
antibodies were diluted to 62.5, 125, 250 and 500 ng/mL. The used concentration of 
strepatividin-HRP was 0.2 µg/mL. The signal generated for each dilution of 
biotinylated antibody was divided by the corresponding background. The highest 
signal-to-noise ratio was obtained when the concentration of 500ng/mL of coating 
antibody was used for each analyte. The example of signal-to-nose ratios generated 
for D assay with different concentration of biotinylated Ab is shown in Figure 12. 
Consequently, a concentration of 500 ng/mL of detection antibody was chosen for 
microarray fabrication. 
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Figure 12: Assay was performed using different concentrations of biotinylated 
antibody. The best signal-to-noise ratio was generated with the concentration of 
500ng/mL of biotinylated Ab for each analyte. The signal-to-noise ratios showed in 
the figure were generated for D assay. 
 
Two different concentrations (0.2 and 0.1 µg/mL) of strepatavin-HRP in assay buffer 
were evaluated (data not shown). There was no significant difference in the assay 
performance comparing these two conditions. Consequently the 0.2 µg/mL 
concentration of streptavidin-HRP was chosen for microarray fabrication.  
 
4.3.2.2 Volume of coating solution per spot  
Different volumes of dispensed coating antibody were tested to check whether this 
parameter can improve the assay performance. 
Antibodies were printed onto the surface of each well in quadruplicate. Each standard 
curve concentration was dispensed into two wells. Consequently 8 spots per analyte 
were generated. The antibodies solutions were dispensed at a volume of ∼0.333 pL 
per drop. Four different cases of total spot volume were investigated: 20nL (60drops), 
10nL (30drops), 3nL (9drops) and 0.333 nL (1drop). The coefficient of variation 
(CV%) on the signal provided by the spots after performing an assay, was calculated 
for each dispensed volume. When 20 nL per drop was dispensed the size of the spots 
was relatively big resulting in spot overlap and subsequent inaccuracies in spot 
assaying. In three other cases CV% of signal intensities generated from each spot was 
calculated for all standard curve concentrations: 10, 25 50 100 and 1000 pg/mL. The 
best sensitivity and CV% was obtained when the volume of 3 nL per spot was 
   42 
dispensed. The CV% range over the standard curve concentration is shown in (Table 
6). As a result the volume of 3nL /spot was chosen for microarray fabrication. 
 
Table 6: Dispensed spot volume. Different volumes of coating antibody solution per 
spot were dispensed for each analyte. CV% was calculated on signal densities 
generated from each spot (n=8) using the formula: (stdev/mean*100). The CV% was 
the best when 3nL / spot volume was dispensed. 
 A C D 
Spotted volume CV% 
0.333 nL 35.4 – 76.8 33.4 – 54.6 11.5 – 105.4  
3 nL 4.7 – 13.3 10.3 – 37.6 6.1 – 12.0  
10 nL 18.2 – 25.2 22.3 – 53.3  11.1 – 30.4 
 
4.3.3 Matrix evaluation 
As recommended by the FDA guidelines for pharmacokinetic immunoassays (Food 
and Drug Administration 2001) standard curve should be prepared in the same matrix 
as the analyzed samples. Alternatively, other species matrixes or analyte free buffer 
can be used. During the microarray development, quantitative curves were produced 
for A and C assays. D quantification, however was not possible when the standard 
curve was prepared in human serum. In order to produce a standard curves that would 
allow for the simultaneous measurement of all analytes of interest; dog, calf, human 
serum pool and analyte free protein based buffer were evaluated as potential matrix’s 
for the standard curves preparation.  
 
4.3.3.1 Human, dog and calf  serum evaluation 
Standards curves for A, C and D were prepared in single dog, human, and calf serum. 
Standard curves generated for D, did not provide the linearity sufficient to perform 
quantitative D measurement (Figure 13). For instance, when human and dog serum 
matrix’s were used for standard curve preparation, D signal generated for the blank 
samples was about 70 times higher compared to the C blank signal. When calf serum 
was used to generate a standard curve this difference was even 700 times higher. 
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Figure 13: Standard curves for A, C, D generated                                                            
in dog, human and calf serum. Local background from each well  
was subtracted from the signal intensities before plotting. 
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4.3.3.2 Buffer evaluation 
Standard curves for A, C and D were prepared in assay buffer used for standard curve 
generation in commercially available ELISA kits (TCM sample diluent – 
ENDOGEN). The obtained standard curves are shown in Figure 14. Human serum 
pool was spiked with recombinant proteins at various concentrations. These samples 
were analysed on the produced standards. The found concentration did not meet the 
spiked amount of each analyte. For instance results obtained for A gave half of the 
values (accuracy ∼ 50%) compare to the spiked amount of A (Table 7). 
 
 
Figure 14: Standard curves obtained for A, C, D prepared  
in assay buffer.  
 
 
Table 7: Accuracies [(spiked analyte concentration/found analyte concentration)*100] 
calculated for human serum samples spiked with A. The accuracies were calculated 
on A standard curve prepared in buffer. The obtained values gave half of the values 
compared to the spiked amount of A  
Spiked  
analyte concentration 
Found analyte concentration Accuracy 
ng/mL ng/mL % 
1.000 0.489 48.9 
0.400 0.193 48.3 
0.160 0.074 46.5 
0.064 0.031 48.3 
0.026 0.014 52.8 
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 4.3.3.3 Different human serums screening 
In order to select the human sera that contain only low levels of A, B, C, D, E, F, 
antibodies against them were printed onto the surface of each well. Different batches 
of human sera were applied onto an array (Figure 15a). Sera that did not provide the 
signal or these for which the generated signal was very low for the investigated 
analytes were selected for pooling (Figure 15b). The amount of endogenous analytes 
in these samples was measured with the use of commercially available ELISA kits in 
order to know to which level do they correspond in the individual samples and in the 
serum pool. These data was needed to use ELISA in the future to screen the sera prior 
pooling, and consequently to prepare the pool itself. In total 36 batches of human sera 
were screened out of which 12 were selected and pooled. Levels of analytes of interest 
in the pool are shown in Table 8. 
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 a) 
 
 
b) 
 
Figure 15: Screening of different batches of human sera. Different batches of human sera 
were applied into each well (marked in blue –(a)) .  Each batch was analyzed in duplicate  
(green (a)). Sera that gave high signal for the printed analytes were rejected. The example of 
the rejected serum is shown in (b) - 2 wells on the right site. 
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 Table 8: Analyte level in the selected human serum pool.  
Analyte Result [ng/mL] 
Analyte levels range in 
normal serum [ng/mL] 
A blq  blq 
B 0.232 0.106 – 1.552 
C blq 0 - 0.149 
D 0.049 0.001 – 0.016 
E blq blq 
F 0.282 0.200 – 0.722 
 
Subsequently standard curves for all analytes were produced in a human serum pool. 
All standards showed satisfactory linearity. The example of A, C, D are shown in 
Figure 16.  
Samples prepared in the same manner as during the buffer matrix evaluation (section 
4.3.3.2, page 44) were measured with the human serum pool standards. The 
determined concentration for all analytes corresponded to the spiked concentrations 
gave the assay accuracy within 70% ≤ and ≤130%. As an example, results for A are 
shown in Table 9. Selected human serum pool was used for the assay validation. 
 
 
 
Figure 16: Standard curves for A, C, D generated  
in human serum pool. Local background from each well was  
subtracted before plotting the signal and concentration. 
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Table 9: Results for A assay. Analyte A human serum spiked samples were measured 
using a standard curve prepared with human serum pool. The concentrations were 
found to lie within the satisfactory accuracy (70% ≤ and ≤130%). 
Spiked  
analyte concentration 
 Found analyte concentration Accuracy 
ng/mL ng/mL % 
1.000 0.798 79.8 
0.400 0.373 93.3 
0.160 0.138 86.2 
0.064 0.055 85.4 
0.026 0.022 87.3 
 
 
4.3.4  Assay condition optimisation 
4.3.4.1 Addition of glycerol into a coating solution 
The influence of glycerol for the assay performance was investigated. PBS both 
without and with, 5 or 10 % addition of glycerol was used as coating solution. The 
spotting device producer recommended the addition of 10% of glycerol as maximum 
amount of glycerol added into a coating solution, due to the technical issues. CV% 
and accuracy was calculated for all standard curve concentration points. The 
representative data for A is shown in Table 10. There was no major differences in 
CV% and Acc% in between the results obtained with the addition of glycerol. 
Addition of glycerol, however, was problematic from the technical point of view. The 
viscous glycerol properties caused the printing tips to clog. Therefore, based on these 
results it was decided not to add glycerol to PBS in preparing coating buffer for 
microarray production. 
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Table 10: Addition of glycerol into a coating solution. 
10 % glycerol 5 % glycerol 0 % glycerol A 
pg/mL CV% Acc% CV% Acc% CV% Acc% 
7.8 7.4 105.1 13.8 99.7 11.3 84.0 
15.6 17.6 108.4 19.7 102.8 26.6 128.9 
31.2 15.3 92.4 12.5 111.5 24.4 119.8 
62.5 16.0 88.4 37.1 83.5 27.1 107.3 
125 19.7 99.9 34.0 94.6 24.0 92.8 
250 16.0 98.9 28.4 106.0 16.2 102.2 
500 8.7 108.4 44.8 108.5 20.3 99.5 
1000 17.8 100.3 34.2 96.3 26.4 100.1 
 
 
4.3.4.2 Assay format 
The developed assay conditions were also applied to co-incubation assay format. In 
case of co-incubation, assay was performed in 1 step. Printed coating antibodies were 
incubated together with the mixture of sample and cocktail of biotinylated antibodies 
(Figure 17). Co-incubation approach could minimize the time difference between the 
sample application into the plate. Another advantage could be assay practicability – 
only one incubation step required, no washing steps in between. In order to evaluate 
the performance of sandwich (2steps) and co-incubation (1 step), the same experiment 
was carried out utilising both formats. The schematic design of both formats is shown 
in Figure 17. For 1 step format the two incubation steps were replaced with one 4h 
incubation of sample mixture (50 µL/well) and biotinyletd antibody (50 µL/well). 
Subsequent steps with strepatvidin-HRP and chemiluminescent substrate were the 
same for both formats. C standard curve represents the standard curves generated with 
the use of both assay formats (Figure 18). When 1 step format was performed the 
generated standard curve linear range augmented, showing the potential to increase 
assay sensitivity. Consequently 1 step protocol was applied for microarray fabrication. 
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 Biot Ab 
2 steps 
Sample 
1 step 
 
Figure 17: 2 and 1 step assay procedure. Two steps protocol consists of two 
incubation steps (2h each): sample is added and incubated with coated antibodies, 
after washing, assay is incubated with biotinylated antibodies. In co-incubation 
protocol, sample and antibodies are added together and incubated for 4 h. There is no 
washing step required. 
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 1 step 
2 steps 
 
Figure 18: Representative C standard curve for an assay performed with two step and 
co-incubation protocol. The obtained results show that 1 step protocol can improve 
assay sensitivity.  
 
4.3.4.3 SAA assay approach 
According to literature SAA level in RA sera is observed at levels ranges from 300 
µg/mL (Charles et al. 1999) up to 1500 µg/mL (Cunnane et al. 2000). The standard 
curve linear range generated for SAA was not sufficient to quantify the biological 
concentration for SAA found in RA patients. Following the hypothesis that the cold 
coating antibody could bind to the analyte (Figure 19) reducing the amount of analyte-
biotinylated antibody complex that could bind to coating Ab, cold monoclonal 
antibody in the amount 20 and 80µg/mL was added into a sample. Theoretically the 
linear part of standard curve could be moved in a manner that the quantification of 
higher concentration of SAA would be possible. Only addition of 80 µg/mL of 
coating antibody showed shift of a standard curve range however the shift was not 
significant enough to measure SAA in biological undiluted samples (Figure 20). This 
approach already made an assay too expensive in comparison to single SAA ELISA 
kit. As a result SAA was removed from the panel of analytes.  
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Figure 19: Approach of adding cold coating antibody into a sample. Cold antibody 
could bind to the analyte reducing the amount of analyte-biotinylated Ab complex 
bound to the capture Ab. This could help to shift SAA standard curve in a manner 
allowing to measure higher SAA concentrations. 
 
 
 
 
 
Figure 20: SAA standard curve range did not cover the biological level of SAA.  
Cold anti SAA monoclonal antibody in the concentration of 20 and 80µg/mL was 
added into a sample in order to optimize standard curve to meet SAA levels in 
biological samples. Only addition of 80µg/mL of an antibody shifted standard curve 
range.  
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4.3.5 CCD camera selection and set up 
Signal visualised using HRP-conjugated streptavidin and chemiluminescence was 
then imaged with the use of charge-coupled device (CCD) camera.  
The choice of chemiluminescence and CCD camera combination was dictated by the 
96-well format. At that time, there was no fluorescence scanner available for 
digitizing the signal from the bottom of 96-well pate. Two CCD cameras were utilized 
for imaging: LAS 1000 and LAS 3000. Figure 21a shows the image of 96-well plate 
digitized with LAS 1000, figure 21b with LAS 3000. The advantage of the second 
camera is a non-parallax tray option eliminating parallax in each of 96 well plate 
wells. The parallax effect causes that the image of the bottom of the well is deformed 
making the spot analysis inadequate. LAS 3000 also gave an option of high resolution 
binning mode which by decreasing the size of the spot makes microarray analysis 
easier and more precise (Figure 21c). In consequence second camera was chosen for 
microarray fabrication.  
 
Various options are available for background measurement: local (area around 
individual spots) or global (area outside of the grid) background corrections, as well 
as user-defined values such as those from negative control data points contained 
within the array may all be employed for analysis. All these options for background 
correction were evaluated (data not shown). Background generated during the assay 
was stable across the all analyte concentrations for all wells of the plate. CV% 
between the background signal intensities from each well was 3.3%. The assay results 
with and without background subtraction were compared. There was no difference in 
assay performance in terms of sensitivity and variability. Based on these results in the 
developed assay there is no background correction performed for the produced signal 
intensities. 
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a) 
 
b) 
 
c) 
 
Figure 21: Images generated with two different CCD cameras: a – LAS 1000, b and c 
– LAS 300. The picture a) shows an image produced without non-parallax tray, 
created edge effect makes an image analysis imprecise. Picture b) and c) was taken 
with the non-parallax tray device. There is no more edge effect b). On the picture c) 
three different image modes are compared: high (left), standard (middle) and high 
resolution mode (right).  
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4.3.6 Quantification software  
To quantify the produced signal many companies offer the specialized quantification 
software. The main issues raised with the signal quantification is analysis 
practicability and precision. Three of the commercially available quantification 
software were evaluated: Aida, ImaGene™ and ArrayVision™. ArrayVision™ 
package was superior over two other software because of the standard curve 
generation feature. Other programs required additional tools for standard curve 
generation. For instance, digitized signal values had to be exported into a Excel 
program to perform the variability calculations. Afterwards the data was again 
exported to Softmax® PRO software for standard curve generation. This was the main 
factor that caused the ArrayVision™ to be chosen as the software for antibody 
microarray fabrication. The comparison of the three software is shown in Table 11. 
 
Table 11: Quantification software comparison. 
 Aida ImaGene™ Array vision™ 
Speed of analysis + +++ +++ 
Auto spot adjustment - + + 
Easy to use + +++ +++ 
Standard curve generation - - + 
 
 
4.3.7 Developed protocol for the miniaturized assay in 96-well format 
As an outcome of all the development steps described above, the protocol for the 
microarray fabrication in a 96-well format to measure serum samples was created. 
This protocol is shown below: 
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Protocol for the microarray generation in a 96-well format 
General reagents: 
Plate   black plate 
Coating buffer  PBS1X 
Matrix   human serum pool 
CCD camera  LAS-3000. High resolution binning mode. 
Software  ArrayVision™ 
 
Assay Protocol:  
Coating  - 200µg/mL of monoclonal Ab,  
   - 3 nL/ spot 
   - 2 hours drying in the Biochip arrayer enclosure 
   - over night incubation at 4ºC 
   - drying 30 minutes at RT 
   - drying 10 minutes at 37ºC 
Blocking  - 3 X 200 µL of SuperBlock/well 
   - 100 µL of SuperBlock/well – 30 minutes incubation RT  
Samples incubation - 50 µL/well of sample 
   - 50 µL/well of cocktail of biotinylated antibodies at 500 ng/mL 
   - 4 hours incubation at room temperature on shaking platform 
   - wash 3 times with wash buffer 300 µL/well 
Streptavidin-HRP - 100 µL/well at concentration 0.2 µg/mL 
- 30 minutes incubation at room temperature on shaking     
   platform 
- wash 3 times with wash buffer 300 µL/well 
Chemiluminescent substrate 
   - 100 µL/well – immediate readout  
Imaging  - CCD camera exposure for 20 second 
   - images digitized and saved as 16-bit tiff files 
Signal quantification - ArrayVision™ 
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4.4 Discussion 
The objective was to develop an efficient method to measure simultaneously serum 
biomarkers in the 96-well format. The main components, steps and conditions that 
make up a microarray fabrication were evaluated. Assessment covered the reagents 
titration, amount of coating antibody per spot deposition, matrix selection, signal 
detection, assay format and analysis software evaluation.  
 
The concentration of 200 µg/mL of coating antibodies produced the most optimal 
signal-to-noise ratio. The reason why the lower concentrations investigated did not 
produce similar signal-to-noise could be caused by the antibodies denaturation during 
the printing process. When the concentration of coating solution was higher, probably 
the amount of Ab that remained in a functional state was sufficient for optimal assay 
performance. Another explanation is the nature of physical adsorption by which 
antibodies are immobilized on the polystyrene 96-well plate. Physical adsorption can 
lead to the protein desorption during the assay, which can lead to signal loss. 
Consequently, when the concentration of coating Abs was higher, even though some 
Abs desorped from the surface, the remained amount was still sufficient to perform an 
assay. 
 
Addition of glycerol as a potential stabilizer to the coating solution could help Abs to 
maintain their functionality. Thus, the influence of glycerol in a coating solution on 
assay performance was investigated. However there was no advantage observed in 
terms of variability and accuracy when the glycerol was added. Maybe the fact that 
antibody spots were in the bottom of the well prevented the spots from drying out and 
created the microenvironment with the conditions that did not denature the mAb.  
 
Existing guidance for pharmacokinetic immunoassays recommend to prepare standard 
curve for analyte measurement in the matrix of the same origin as the analyzed 
samples. Alternatively the heterologus animal matrix or analyte free buffer could be 
used. During the microarray development the linearity obtained for D standard curve 
prepared in human serum, did not allow for D quantification. Probably serum used to 
generate standard curve contained endogenous D that introduced bias in the analyte 
measurement. Precise D quantification was only possible in the selected pool of 
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human sera that contained low levels of endogenous analytes of interest. This 
approach however has its limitations. Might be that for a different panel of analytes 
this kind of pool could never be selected. In such situation the compromise has to be 
taken: either the problematic analytes should be excluded from the set of analyzed 
markers, or other matrixes such as analyte free buffer should be used as matrix. 
Choosing the second option though, the spike recovery investigations have to be 
performed and necessary corrections included in the results calculations. For instance 
for the panel of markers for which the microarray was developed in the above chapter 
the accuracy of spiked A was about 50 % when buffer was used as a matrix. This 
justify the need of assay performance validation and necessary results corrections. 
 
The light produced in chemiluminescence reaction is emitted equally in all directions. 
That is why it is recommended to use black instead of clear plates for the 
chemiluminescence measurements in order to avoid so called light piping 
phenomenon. Light piping is simply the interference of the signal generated from each 
spot and well. Black plates however require the image to be taken from above the 
plate which creates the danger of introducing the parallax error. Therefore we 
compared two kinds of CCD camera as imaging tool for the antibody array. The non 
parallax tray option provided by LAS 3000 camera allowed for imaging the whole 
plate with no parallax effect. In the future, the availability of the scanner to image 
microarray in a 96-well format could allow changing to fluorescence signal 
generation. This could help to avoid light piping as well as stable, multi-readable 
signal production.   
 
Described results demonstrate the microarray development steps and conditions. 
However the applicability of the platform to the real samples measurement, its 
reproducibility, and accuracy need to be validated. The individual validation steps are 
described in the following chapters. 
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5 Validation of Antibody microarray in 96-well plate 
5.1 Introduction 
The developed antibody microarray in 96-well plate is based on a sandwich ELISA 
procedure utilized in classical immunoassays (Wild 2001). Immunoassays are 
frequently applied for biomarkers quantification in clinical studies (Findlay et al. 
2000). Thus, it is very important for the immunoassay to be accurate and precise. 
Accuracy, is defined as the closeness of the concentration value obtained by the 
method to the known true concentration value of the analyte. Precision is the 
closeness of individual measures of an analyte when the method is applied repeatedly 
to multiple aliquots of the same biological sample. 
 
• Accuracy = (calculated concentration/nominal concentration)*100.  
• Precision = (standard deviation/calculated mean concentration)*100 
 
These key characteristics of any bioanalytical method are investigated during the 
process of validation. Validation of an analytical method identifies the sources and 
quantifies the potential errors in the method (Findlay et al. 2000; Shah et al. 2000). An 
assay validation describes in mathematical and quantifiable terms the performance 
characteristics of an assay. Classical immunoassays have to be validated in line with 
the FDA directives (Food and Drug Administration 2001). Such regulations do not 
exist for biomarkers and multiplex assays. Therefore, in order to validate the 
developed antibody microarray, the protocol that followed the FDA guidelines for 
industry for pharmacokinetic immunoassays validation (Food and Drug 
Administration 2001) was established. The validation covered the assessment of the 
methods robustness and reproducibility. A spike-recovery validation test was 
elaborated and run over 3 days.  
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5.2 Materials and methods 
5.2.1 Validation protocol 
The protocol adopted for validation of the Ab microarray was based on FDA 
directives for pharmacokinetic immunoassays (Food and Drug Administration 2001). 
The following section describes the process used to validate the Ab microarray. A 
modified protocol adopted for Ab microarray in a 96-well format that was 
implemented for the validation process is shown below:  
 
Validation protocol of antibody microarray in 96-well plate: 
Matrix 
Matrix is used to describe a biological medium like plasma, serum, whole blood, 
urine, faeces, tissue, from which the analyte(s) is quantified. 
All validation experiments were performed on a selected pool (n=12) of human serum 
containing low levels of the measured analytes. 
 
Standard curve 
The standard curve is a relationship between instrument response and known 
concentration of analyte. 
• The linear part of standard curve should lie within the analyte concentration 
 levels in the disease state. The standard curve was constructed using 8 
 different concentration levels. The samples were blanked with sample to 
 which  neither analyte(s) nor internal standard had been added. 
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Table 12: Concentrations of standard curve points.  
 
 Std 1 Std 2 Std 3 Std 4 Std 5 Std 6 Std 7 Std 8 Std9 
ng/mL 
A blank 0.023 0.047 0.094 0.188 0.375 0.750 1.500 3.000 
B blank 0.090 0.180 0.359 0.719 1.438 2.875 5.750 11.500
C blank 0.023 0.047 0.094 0.188 0.375 0.750 1.500 3.000 
D blank 0.023 0.047 0.094 0.188 0.375 0.750 1.500 3.000 
E blank 0.117 0.234 0.469 0.938 1.875 3.750 7.500 15.000
F blank 0.014 0.027 0.055 0.109 0.219 0.438 0.875 1.750 
• Standards in matrix must be  freshly prepared and run on each (n=3) validation 
day. 
• Standards were prepared singly and analyzed in triplicates. 
• Back-calculated values for the standards within the working range should give 
≤30% deviation from the expected concentration (70% ≤ Accuracy ≤130%). 
• Precision should be ≤ 30% at each concentration level 
• Maximally 1/4 of the individual standards can be excluded. 
• At least 50% of the values (spots) at each standard concentration must be 
within accuracy and precision range. 
 
Quality control samples 
Quality control sample (QC) is a spiked sample used to monitor the performance of a 
bioanalytical method and to assess the integrity and validity of the results of the 
unknown samples analyzed in an individual batch. QC is prepared in the same matrix 
as standard the curve. 
• QC samples were prepared in six concentration levels for each analyte.  
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Table 13: Concentrations of quality control samples. 
 
 QC1 QC2 QC3 QC4 QC5 QC6 
ng/mL 
A 0.026 0.064 0.160 0.400 1.00 2.500 
B 0.092 0.230 0.576 1.440 3.600 9.000 
C 0.026 0.064 0.160 0.400 1.00 2.500 
D 0.026 0.064 0.160 0.400 1.00 2.500 
E 0.128 0.320 0.800 2.000 5.000 12.500 
F 0.015 0.038 0.096 0.240 0.600 1.500 
• Two QC sets were prepared from the same matrix independently for each QC 
concentration and analyzed in triplicates. 
• The QC samples should cover the anticipated dynamic concentration range, 
with one QC at the anticipated lower limit of quantification (LLOQ); one 
within 3 times the LLOQ, one approximately between the high and low QC 
concentrations and one close to the anticipated upper limit of quantification 
(ULOQ). 
LLOQ is the lowest concentration of analyte in a sample that can be 
quantitatively determined with suitable precision and accuracy. 
ULOQ is the highest amount of analyte in a sample that can be quantitatively 
determined with suitable precision and accuracy. 
• 70% ≤ Accuracy ≤130%  based on the mean value at each concentration level 
• Precision ≤ 30% at each concentration level 
• At least 2/3 of the individual QC concentration values must be within accuracy 
and precision range 
• At least 50% of the values (spots) at each QC concentrations must be within 
accuracy and precision range. 
• Standards and QC prepared from the same stock solution  
• Inter-day variability: 3 validation runs performed on different days.  A 
validation run should be rejected only if there is an analytical problem (e.g. an 
error in reagents preparation, instrument failure, pipetting error or if the data 
from a run are so erratic that the values could only have resulted from an 
unexplained analytical errors.) 
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 Stability 
Stability is a physico-chemical constancy of an analyte in a given solution or matrix 
under specific storage conditions for given time intervals. 
• Short-term stability of spiked samples. Stability of the stock spiking human 
serum pool of analyte to be evaluated at RT for at least 6 hours. After 
completion of the desired storage time, the stability should be tested by 
measuring stored vs. freshly prepared samples. The stability will be tested on 
QC3 and QC4 (the most representative concentrations for the standard curve 
linear range). 
• Long-term stability: The QC3 and QC4 prepared for inter-day variability 
validation will be analysed on first validation run, in 1 week interval and 1 
month interval. 
 
5.2.2 Calibrators and QC samples preparation 
The same stock solution was used for the preparation of standards and QC samples for 
each analyte. Standards and QC samples were freshly prepared on each analysis day 
from the same pool of human serum. The concentrations ranges covered for standards 
and QC were as indicated in validation protocol.  
 
5.2.2.1 Calibrators preparation 
The pre sample solution was prepared in human serum pool using an analyte stock 
solution  of 20 µg/mL. The stock solution was diluted two times (1:10) in human 
serum pool to the concentration 10 ng/mL. To prepare the target concentration of A, 
B, C, D and E the 100 ng/mL concentration was used. For F - 10 ng/mL. The cocktail 
of recombinant proteins in human serum was diluted 1:2 in human serum in serial 
dilutions to the target concentrations defined in the validation protocol. The standard 
curve was obtained by plotting the signal versus concentration, using logistic (ELISA) 
settings in ArrayVision™ for each analyte. The quality of the individual calibration 
lines was assessed from the accuracies and precision of the back calculated 
concentrations of the calibration standards. These accuracies were calculated with use 
of SOFTmax® PRO software. 
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Calculations 
Accuracy % and Precision %: 
Mean  of at least 50% of all spots (n=6) for each standard concentration 
CV%  (SD of at least 50% of all spots for each standard concentration /  
  Mean)*100% 
 Acc%  (observed concentration / expected concentration)*100% - based on 
  the mean value at each concentration level. 
 
5.2.2.2 QC sample preparation 
The pre sample solution was prepared in human serum pool from the stock solution 
20 µg/mL for each analyte. The stock solution was diluted two times (1:10) in human 
serum pool to the concentration 10 ng/mL. To prepare the target concentration of A, 
B, C, D and E the 100 ng/mL concentration was used. For F - 10 ng/mL. The cocktail 
of recombinant proteins in human serum was diluted 1:2.5 in serial dilutions to the 
target concentrations defined in the validation protocol. Calculating the inter-day 
accuracy and precision and the intra-day accuracy and precision of the QC samples 
analyzed together with calibration samples on each day (n=3) assessed the accuracy 
and precision of the method. QC were prepared in triplicates, 2 spots per well (n=12) 
for two independent QC sets. The accuracy and precision for QC samples were 
calculated with ArrayVision™ software using following formulas. 
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Calculations 
Intra-day accuracy % and precision %: 
Mean  of at least 50% of all spots (n=12) for each QC concentration 
CV%  (SD of at least 50% of all spots for each QC concentration /  
  Mean)*100% 
 Acc%  (observed concentration / expected concentration)*100% - based on 
  the mean value at each concentration level. 
Inter-day accuracy % and precision %: 
Mean  of at least 50% of all spots (n=36) from 3 validation days for each QC 
  concentration 
CV%  (SD of at least 50% of all spots from 3 validation days for each QC 
  concentration / Mean)*100% 
Acc%  (observed concentration / expected concentration)*100% - based on 
  the mean value at each concentration level. 
 
5.2.3 Stability sample preparation 
Human serum pool was spiked with the recombinant proteins at the concentrations 
corresponding to QC3 and QC4 for each analyte. The samples were analyzed in 
triplicates for two sets prepared independently. Stability of spiked human serum was 
measured after storage for 8 h at RT on each validation day. Fresh samples were 
prepared every day and stored for 8 h at RT. In case of  1 week and 1 month storage at 
- 80ºC, samples were prepared on the first validation day. The stability was 
investigated in single experiments after particular storage time calculating the data of 
stored samples on the freshly prepared standard curve. 
 
5.2.4 Assay procedure 
Experiments on each validation day were performed according to the protocol 
described in section 4.3.7. 
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5.3 Results 
5.3.1 Calibration curve  
A calibration curve was established on each validation day (total of 3 days) using the 
concentration of calibrants as described in the validation protocol. The typical 
standard curves obtained are shown in Figure 22. For A, C, D and F precision and 
accuracy for all calibrants were within the acceptance criteria. For the B and E 
standards, accuracy and precision fulfilled the acceptance criteria for all samples 
except for the lowest calibration samples. The B lowest calibration sample, 0.090 
ng/mL, gave an precision of 40.2% (average of the precision obtained on each 
validation day). The accuracy met the acceptance criteria though. The E lowest 
calibration sample, 0.117 ng/mL, gave an average accuracy and precision from 3 
validation days of 198.3% and 38.5% respectively (Table 14 and Table 15). 
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A1000
10000
100000
0.01 0.1 1 10
ng-mL
ID
V
B
1000
10000
100000
0.01 0.1 1 10 100
ng-mL
ID
V
 
C
1000
10000
100000
0.01 0.1 1 10
ng-mL
ID
V
D
1000
10000
100000
0.01 0.1 1 10
ng-mL
ID
V
E
1000
10000
100000
0.01 0.1 1 10 100
ng-mL
ID
V
F
1000
10000
100000
0.001 0.01 0.1 1 10
ng-mL
ID
V
 
Figure 22: Typical standard curve and calibration results for each analyte. Standard 
curves were prepared in human serum pool on each validation day using the 
concentrations indicated in the validation protocol. The signal density is defined as the 
integrated data value (IDV). The signal was plotted against the analyte concentration 
using a logistic ELISA fit. 
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Table 14: Mean accuracy of back-calculated concentrations of calibration samples.  
The back-calculated values for each standard curve concentration was accessed with 
SOFTmax® PRO software. Mean accuracy was calculated on at least 50% of all spots 
(n=6) for each standard concentration.  
A 
[ng/mL] 3.000 1.500 0.750 0.375 0.188 0.094 0.047 0.023
Accuracy (%) 
Day 1 
Day 2 
Day 3 
100.7 
101 
102.3 
103.5 
99.8 
93.2 
96.7 
98.4 
110.6 
98.3 
106.4 
96.4 
105.5 
104.8 
100.3 
109.2 
98.8 
91.1 
98.5 
94.3 
90.8 
94.9 
80.4 
87.1 
 
B 
[ng/mL] 11.500 5.750 2.875 1.438 0.719 0.359 0.180 0.090
Accuracy (%) 
Day 1 
Day 2 
Day 3 
96.2 
97.9 
97.8 
107.7 
105.3 
107.6 
97.0 
94.3 
92.7 
99.0 
96.9 
98.9 
102.6 
114.2 
108.2 
108.6 
107.7 
113.1 
121.9 
127.6 
113.1 
106.9 
103.9 
93.7 
 
C 
[ng/mL] 3.000 1.500 0.750 0.375 0.188 0.094 0.047 0.023
Accuracy (%) 
Day 1 
Day 2 
Day 3 
100.1 
100.8 
100.4 
100.5 
100.4 
98.6 
99.0 
99.7 
103.4 
101.5 
98.7 
98.3 
97.8 
104.7 
103.6 
103.3 
98.7 
96.3 
107.8 
96.6 
97.8 
108.3 
114.9 
104.6
 
D 
[ng/mL] 3.000 1.500 0.750 0.375 0.188 0.094 0.047 0.023
Accuracy (%) 
Day 1 
Day 2 
Day 3 
100.2 
100.0 
100.0 
101.7 
100.7 
100.0 
97.6 
98.6 
100.1 
97.9 
99.8 
101.2 
103.9 
103.2 
99.2 
112.4 
100.4 
96.0 
109.4 
101.6 
100.9 
76.3 
100.2 
110.0
 
E 
[ng/mL] 15.000 7.500 3.750 1.875 0.938 0.469 0.234 0.117
Accuracy (%) 
Day 1 
Day 2 
Day 3 
102.9 
89.9 
101.7 
94.4 
105.0 
99.8 
107.6 
96.6 
101.9 
91.2 
96.1 
97.3 
89.1 
114.2 
90.2 
105.7 
123.1 
110.9 
128.0 
121.4 
86.4 
201.0 
247.5 
146.4
 
F 
[ng/mL] 1.750 0.875 0.438 0.219 0.109 0.055 0.027 0.014
Accuracy (%) 
Day 1 
Day 2 
Day 3 
100.1 
100.2 
100.3 
100.3 
100.2 
98.9 
99.1 
100.8 
101.2 
99.2 
94.1 
101.3 
102.4 
110.8 
104.5 
115.2 
107.1 
103.9 
106.9 
101.1 
99.9 
93.1 
126.5 
85.8 
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Table 15: Mean precision of back-calculated concentrations of calibration samples. 
The back-calculated values for each standard curve concentration was assessed with 
SOFTmax® PRO software. Mean precision was calculated on at least 50% of all spots 
(n=6) for each standard concentration 
A 
[ng/mL] 3.000 1.500 0.750 0.375 0.188 0.094 0.047 0.023 
 
Precision (%) 
 
Day 1 
Day 2 
Day 3 
18.2 
25.7 
24.3 
14.1 
21.5 
8.6 
8.9 
24.9 
21.4 
12.0 
23.2 
16.9 
13.8 
14.9 
12.5 
15.4 
11.3 
12.8 
11.7 
15.8 
14.5 
18.3 
18.3 
18.1 
 
B 
[ng/mL] 11.500 5.750 2.875 1.438 0.719 0.359 0.180 0.090 
 
Precision (%) 
 
Day 1 
Day 2 
Day 3 
6.5 
9.7 
11.3 
21.1 
7.3 
13.4 
19.7 
5.5 
4.6 
17.3 
11.0 
11.5 
18.7 
8.5 
9.5 
17.6 
15.9 
16.3 
27.6 
22.0 
17.5 
31.3 
61.5 
27.8 
 
C 
[ng/mL] 3.000 1.500 0.750 0.375 0.188 0.094 0.047 0.023 
 
Precision (%) 
 
Day 1 
Day 2 
Day 3 
8.7 
23.8 
15.2 
11.8 
15.4 
11.9 
8.5 
12.6 
13.5 
13.1 
13.9 
10.7 
5.3 
11.5 
3.4 
11.2 
10.2 
6.3 
27.6 
17.5 
21.8 
24.1 
27.8 
29.2 
 
D 
[ng/mL] 3.000 1.500 0.750 0.375 0.188 0.094 0.047 0.023 
 
Precision (%) 
 
Day 1 
Day 2 
Day 3 
15.0 
5.0 
3.4 
15.0 
9.2 
9.7 
18.4 
6.9 
9.5 
17.5 
5.4 
9.1 
14.2 
6.0 
12.3 
27.7 
11.8 
9.9 
20.0 
8.4 
22.9 
27.1 
28.2 
25.7 
 
E 
[ng/mL] 15.000 7.500 3.750 1.875 0.938 0.469 0.234 0.117 
 
Precision (%) 
 
Day 1 
Day 2 
Day 3 
12.6 
22.7 
21.0 
4.5 
21.7 
14.7 
26.2 
17.1 
17.1 
19.5 
14.5 
18.2 
15.4 
18.8 
23.8 
4.9 
13.9 
21.4 
7.8 
10.6 
28.3 
23.7 
42.7 
49.2 
 
F 
[ng/mL] 1.750 0.875 0.438 0.219 0.109 0.055 0.027 0.014 
 
Precision (%) 
 
Day 1 
Day 2 
Day 3 
4.4 
6.6 
4.7 
6.9 
8.8 
2.9 
10.7 
6.3 
4.6 
6.3 
10.7 
7.2 
5.3 
12.7 
8.0 
9.2 
11.3 
10.2 
10.5 
17.7 
11.6 
28.3 
9.5 
27.7 
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5.3.2 Quality control samples 
The results for intra-day accuracy and precision, and inter-day accuracy and precision 
are shown in Table 16 and Table 17 and Table 18 respectively. All QC samples met 
the acceptance criteria for intra and inter-day assay accuracy and precision. 
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Table 16: Intra-day Accuracy. Individual accuracy of calculated concentrations of 
each QC concentration for all analytes. 
 
A 
QC level Accuracy(%) 
[ng/L] Day 1 Day 2 Day 3 
2.500 96.0 81.8 96.6 
1.000 97.6 103.4 112.7 
0.400 93.4 108.4 101.2 
0.160 85.9 94.7 86.7 
0.064 93.3 86.7 83.7 
0.026 89.4 93.6 103.8 
B 
QC level Accuracy(%) 
[ng/L] Day 1 Day 2 Day 3 
9.000 116.1 122.3 126.1 
3.600 113.8 125.3 115.4 
1.440 110.2 114.7 112.6 
0.576 111.0 100.4 117.0 
0.230 111.5 111.7 125.3 
0.092 128.1 121.6 112.6 
 
C 
QC level Accuracy(%) 
[ng/L] Day 1 Day 2 Day 3 
2.500 99.2 94.7 102.0 
1.000 100.4 97.8 112.5 
0.400 103.7 101.8 113.7 
0.160 101.7 97.7 107.9 
0.064 111.2 93.5 102.4 
0.026 115.9 79.8 112.2 
D 
QC level Accuracy(%) 
[ng/L] Day 1 Day 2 Day 3 
2.500 95.1 98.0 98.6 
1.000 106.4 100.4 107.8 
0.400 106.2 101.7 114.3 
0.160 94.3 95.6 105.9 
0.064 94.2 93.9 105.5 
0.026 89.1 100.1 98.4 
 
E 
QC level Accuracy(%) 
[ng/L] Day 1 Day 2 Day 3 
12.500 105.5 98.3 104.9 
5.000 89.1 81.5 107.5 
2.000 75.5 82.3 92.4 
0.800 78.8 85.0 94.8 
0.320 85.5 105.7 106.6 
0.128 127.4 127.2 112.3 
F 
QC level Accuracy(%) 
[ng/L] Day 1 Day 2 Day 3 
1.500 96.4 94.5 98.1 
0.600 97.3 95.9 106.0 
0.240 101.0 96.5 105.7 
0.096 97.1 91.2 100.6 
0.038 95.3 84.5 93.3 
0.015 90.4 103.5 78.6 
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Table 17: Intra-day Precision. Individual precision of calculated concentrations of 
each QC concentration for all analytes.  
 
A 
QC level Precision(%) 
[ng/L] Day 1 Day 2 Day 3 
2.500 23.4 20.7 24.5 
1.000 15.2 20.4 23.8 
0.400 13.7 22.8 23.3 
0.160 14.8 23.1 18.7 
0.064 25.2 17.0 15.5 
0.026 14.2 23.0 9.0 
B 
QC level Precision(%) 
[ng/L] Day 1 Day 2 Day 3 
9.000 23.4 21.2 12.4 
3.600 15.2 13.9 13.7 
1.440 13.7 17.8 15.7 
0.576 14.8 25.5 20.8 
0.230 25.2 22.0 28.5 
0.092 14.2 23.7 24.8 
 
C 
QC level Precision(%) 
[ng/L] Day 1 Day 2 Day 3 
2.500 11.6 14.9 19.5 
1.000 6.9 15.1 14.5 
0.400 8.4 13.1 15.9 
0.160 10.9 16.4 14.1 
0.064 17.2 15.2 14.2 
0.026 25.1 28.7 27.5 
D 
QC level Precision(%) 
[ng/L] Day 1 Day 2 Day 3 
2.500 12.2 10.3 9.5 
1.000 12.0 6.8 9.6 
0.400 12.5 10.7 14.0 
0.160 17.7 14.8 17.5 
0.064 23.6 17.8 26.8 
0.026 28.1 26.3 21.7 
 
E 
QC level Precision(%) 
[ng/L] Day 1 Day 2 Day 3 
12.500 24.6 27.2 17.1 
5.000 19.2 15.4 22.0 
2.000 18.7 18.9 21.7 
0.800 17.3 24.1 27.6 
0.320 24.8 24.8 28.4 
0.128 21.1 3.3 29.8 
F 
QC level Precision(%) 
[ng/L] Day 1 Day 2 Day 3 
1.500 9.5 10.0 8.6 
0.600 8.5 8.6 7.6 
0.240 13.3 11.2 8.8 
0.096 12.8 11.6 17.3 
0.038 13.3 17.1 17.4 
0.015 24.5 22.8 29.4 
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Table 18: Inter-day accuracy and precision. The range of accuracy and precision over 
the all QC sample concentrations. 
 Accuracy% Precision% 
A 87.9 – 104.6 17.5 – 24.3 
B 109.5 – 121.1 14.7 – 26.3 
C 98.6 – 106.8 14.0 – 28.9 
D 96.0 – 107.4 10.3 – 28.9 
E 83.4 – 122.1 21.8 – 28.3 
F 89.2 – 101.1 9.4 – 27.9 
 
5.3.3 Assay working range 
The assay working range was determined between the LLOQ and the ULOQ (Table 
19). 
 
Table 19: Assay working range determined by between the LLOQ and the ULOQ. 
Analyte Assay working range 
pg/mL 
A 26 - 2500 
B 230 - 9000 
C 26 - 2500 
D 26 - 2500 
E 320 – 12500 
F 15 - 1500 
 
5.3.4 Stability  
All the analytes except for E were stable after 8 h at RT and after 1 week at -80°C 
storage. After 1 month storage at -80°C, the concentration of the spiked samples were 
three time less when compared to the spiked nominal value. These results are shown 
in Table 20 for RT storage determination, and in Table 21 for one week and 1 month 
storage at -80°C. 
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Table 20: Short-term stability. Accuracy of calculated concentration of each QC samples 
after 8h of storage at RT. Fresh samples were prepared on each validation day. 
Day 1 Day 2 Day 3 
Analyte 
QC 
Nominal value [ng/mL] Accuracy % 
0.4 110.2 88.2 88.0 
A 
0.16 80.2 79.9 71.5 
1.44 98.7 102.4 87.6 
B 
0.58 111.8 104.6 96.1 
0.4 93.7 96.4 77.6 
C 
0.16 95.6 97.6 84.9 
0.4 112.8 111.9 88.6 
D 
0.16 110.2 105.1 89.2 
2 53.5 70.0 71.0 
E 
0.8 50.9 60.6 70.3 
0.24 106.3 92.0 80.4 
F 
0.096 94.9 84.0 75.0 
 
Table 21: Long-term stability of spiked samples. Accuracy of calculated concentration of 
each QC samples after 1 week storage at -80ºC and 1 month of storage at -80ºC. 
After 1 week at  
-80ºC 
After 1 month at 
 - 80ºC Analyte 
QC 
Nominal value [ng/mL] 
Accuracy % 
0.4 94.6 35.7 
A 
0.16 74.1 24.7 
1.44 97.7 43.6 
B 
0.58 94.6 35.0 
0.4 101.7 57.3 
C 
0.16 96.7 41.4 
0.4 97.5 25.1 
D 
0.16 87.2 blq 
2 45.9 27.0 
E 
0.8 23.6 41.4 
0.24 89.7 53.7 
F 
0.096 80.3 31.9 
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5.4 Discussion 
Immunoassay as a technology used for biomarker quantification needs to be validated 
in terms of accuracy, precision and reproducibility (Findlay et al. 2000). The antibody 
microarray in 96-well format was validated according to the protocol created at basis 
of the Food and Drug Administration guidelines for pharmacokinetic assays (Food 
and Drug Administration 2001). The following parameters were investigated during 
the validation process: calibrants accuracy and precision based on back calculated 
values; intra and inter day accuracy and precision based on quality control samples; 
stability of antigen spiked human serum samples after 8h storage at RT as well as 
after 1 week and 1 month storage at -80ºC; assay WR based on LLOQ and ULOQ.  
 
The obtained data showed that the assay working range met the disease concentrations 
for the measured analytes. Accuracy and precision for all calibration samples for A, 
C, D, and F analytes fulfilled the acceptance criteria. In case of E accuracy and 
precision and for B only precision for the lowest concentration of standard curve did 
not covered the acceptance criteria. That could be caused by recombinant proteins 
instability or precipitation. Could be that recombinant proteins are degraded by the 
serum components. Another reason might be the binding of the proteins to the soluble 
endogenous receptors in serum matrix or naturally occurring heterophilc antibodies 
(Hennig et al. 2000). However these samples were excluded during the assay working 
range determination. Overall the validation was successful because the assay working 
range covered the examined analytes levels in RA serums.  
 
All samples were stable after 8 hours storage at RT determined on 3 validation days 
and after 1 week storage at -80ºC except for E. None of the samples were stable after 
1 month storage at -80ºC. The inaccuracy of stored samples might be caused by 
antigen precipitation or degradation in the presence of endogenous proteins, as in case 
of E quality control samples were not stable after 8 h storage at RT as well as 1 week 
and 1 month storage at -80ºC. The above results raise the question if similar E 
instability would be found for naturally occurring E in real samples as well? This 
aspect could be investigated by measuring the E levels  in stored  real samples in 
different time intervals. Due to the lack of resources and time this experiments were 
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not covered by this thesis. The above findings indicate that quality control samples 
should be freshly prepared on each measurement day. 
 
Validation results demonstrate that antibody microarray in 96-well plate is accurate, 
precise and reproducible within the determined assay working range. However the 
platform needs to be validated with the real samples. 
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6 Comparison of antibody microarray and ELISA technology 
6.1 Introduction 
ELISA is a standard method for analyzing protein levels in serum samples and has 
been broadly used for the detection of serum cytokines in clinical and microbiological 
research over the last decade (Klimiuk et al. 2002; Lloyd et al. 1991; Mangge et al. 
1995). In this section the performance of protein microarray validated in Chapter 5 is 
compared with the ELISA technology. A, B, C, D, E and F levels in 78 distinct sera 
from rheumatic patients and healthy individuals were measured twice, once by the 
developed protein microarray and once by ELISA. Subsequently the results obtained 
with both methods were compared using linear regression analysis. 
 
6.2 Materials and methods 
6.2.1 Multiplex assay 
The serum concentrations of A, B, C, D, E and F were measured with protein 
microarray validated in chapter 5.  
 
6.2.2 ELISA assay  
Sandwich ELISA was prepared with the same reagents that were used for microarray 
fabrication for antibodies matched pairs and recombinant proteins respectively. Also 
the same serum pool was used to prepare standard curves and QC samples with the 
concentration points identical as used to produce antibody microarray (Table 12 and 
Table 13 page 62 and 63). Briefly, the ELISA protocols for each analyte are 
summarized below. 
 
A 
1. Coating  concentration 3µg/mL in 0.03M Sodium Carbonate/0.068 Sodium 
Bicarbonate, 100µL/well 
2. Incubation at 25ºC overnight 
3. Emptying the plate 
4. Blocking 200 µL/well of PBS with 4%BSA, 
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5. Incubation (1h) at 25ºC 
6. Wash, 300 µL/well of 50 mM Tris, 0.2% Tween-20, 3 times 
7. 50 µL/well of standards and samples 
8. Incubation (1h) at 25ºC 
9. 50 µL/well of biotinylated Ab at 500ng/mL 
10. Incubation (1h) at 25ºC 
11. Wash like in 6. 
12. Streptavidin-HRP (N100, Pierce, stock diluted 1:15000, 100 µL/well 
13. Incubation (30 min) at 25ºC 
14. Wash like in 6 
15. TMB substrate solution (N301 Pierce), 100 µL/well 
16. Incubation 30 minutes at 25ºC 
17. Stop solution (0.18 M H2SO4), 100 µL/well 
18. Absorbance measured at 450 nm minus 550 nm 
 
B 
1. Coating  concentration 5µg/mL in PBS, 100µL/well 
2. Incubation at 25ºC overnight 
3. Emptying the plate 
4. Blocking 200 µL/well of Super block, 3 times 
5. Incubation (1h) at 25ºC 
6. Wash, 300 µL/well of 50 mM Tris, 0.2% Tween-20, pH 8, 3 times 
7. 50 µL/well of standards and samples 
8. 50 µL/well of biotinylated Ab at 500ng/mL 
9. Incubation (4h) at 25ºC 
10. Wash like in 6. 
11. Streptavidin-HRP (N100, Pierce, stock diluted 1:15000, 100 µL/well 
12. Incubation (30 min) at 25ºC 
13. Wash like in 6 
14. TMB substrate solution (50-76-00, Kirkegaard & Perry), 100 µL/well 
15. Incubation 8 minutes at 25ºC 
16. Stop solution (1 M H2SO4), 100 µL/well 
17. Absorbance measured at 450 nm minus 550 nm 
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C 
1. Coating concentration 3µg/mL in PBS, 100µL/well 
2. Incubation at 25ºC overnight 
3. Emptying the plate 
4. Blocking 200 µL/well of PBS with 4%BSA, 
5. Incubation (1h) at 25ºC 
6. Wash, 300 µL/well of 50 mM Tris, 0.2% Tween-20, 3 times 
7. 50 µL/well of biotinylated Ab at 500ng/mL 
8. 50 µL/well of standards and samples 
9. Incubation (2h) at 25ºC 
10. Wash like in 6. 
11. Streptavidin-HRP (N100, Pierce, stock diluted 1:15000, 100 µL/well 
12. Incubation (30 min) at 25ºC 
13. Wash like in 6 
14. TMB substrate solution (N301 Pierce), 100 µL/well 
15. Incubation 10 minutes at 25ºC 
16. Stop solution (0.18 M H2SO4), 100 µL/well 
17. Absorbance measured at 450 nm minus 550 nm 
 
D 
1. Coating concentration 6µg/mL in PBS, 100µL/well 
2. Incubation at 25ºC overnight 
3. Emptying the plate 
4. Blocking 200 µL/well of PBS with 4%BSA, 
5. Incubation (1h) at 25ºC 
6. Wash, 300 µL/well of 50 mM Tris, 0.2% Tween-20, 3 times 
7. 50 µL/well of PBS with 4%BSA 
8. 50 µL/well of standards and samples 
9. Incubation (1h) at 25ºC 
10. Wash like in 6 
11. 100 µL/well of biotinylated Ab at 500ng/mL 
12. Incubation (1h) at 25ºC 
13. Wash like in 6. 
14. Streptavidin-HRP (N100, Pierce, stock diluted 1:15000, 100 µL/well 
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15. Incubation (30 min) at 25ºC 
16. Wash like in 6 
17. TMB substrate solution (N301 Pierce), 100 µL/well 
18. Incubation 30 minutes at 25ºC 
19. Stop solution (0.18 M H2SO4), 100 µL/well 
20. Absorbance measured at 450 nm minus 550 nm 
 
E 
1. Coating concentration 2µg/mL in PBS, 100µL/well 
2. Incubation at 25ºC overnight 
3. Wash, 300 µL/well of 50 mM Tris, 0.2% Tween-20, 3 times 
4. Blocking 200 µL/well of Super block 
5. Wash like in 3. 
6. 50 µL/well of standards and samples 
7. 50 µL/well of biotinylated Ab at 500ng/mL 
8. Incubation (4h) at 25ºC 
9. Wash like in 3. 
10. Streptavidin-HRP (N100, Pierce, stock diluted 1:15000, 100 µL/well 
11. Incubation (30 min) at 25ºC 
12. Wash like in 3. 
13. TMB substrate solution (50-76-00, Kirkegaard & Perry), 100 µL/well 
14. Incubation 15 minutes at 25ºC 
15. Stop solution (1 M H2SO4), 100 µL/well 
16. Absorbance measured at 450 nm minus 550 nm 
 
F 
1. Coating concentration 6µg/mL in PBS, 100µL/well 
2. Incubation at 25ºC overnight 
3. Emptying the plate 
4. Blocking 200 µL/well of PBS with 4%BSA 
5. Incubation (1h) at 25ºC 
6. Wash, 300 µL/well of 50 mM Tris, 0.2% Tween-20, 3 times 
7. 50 µL/well of standards and samples 
8. Incubation (1h) at 25ºC 
   81 
9. 50 µL/well of biotinylated Ab at 500ng/mL 
10. Incubation (1h) at 25ºC 
11. Wash like in 6. 
12. Streptavidin-HRP (N100, Pierce, stock diluted 1:15000, 100 µL/well 
13. Incubation (30 min) at 25ºC 
14. Wash like in 6. 
15. TMB substrate solution (N301 Pierce), 100 µL/well 
16. Incubation 30 minutes at 25ºC 
17. Stop solution (0.18 M H2SO4), 100 µL/well 
18. Absorbance measured at 450 nm minus 550 nm 
 
6.2.3 Samples 
Samples comprised of 52 sera of RA and other arthritic patients as well as 26 control 
human sera. In addition human serum pool was spiked with recombinant A, C, D and 
F and the concentration of 3, 1.500, 0.750, 0.375, 0.188, 0.094, 0.047, 0.023, 0.012 
and 0.006 ng/mL, B ( 0.023, 0.047, 0.094, 0.188, 0.375, 0.750, 1.5, 3.0, 6.0, 12 
ng/mL) and E and the concentration of 0.020, 0.039, 0.078, 0.156, 0.313, 0.625, 
1.250, 2.5, 5.0, 10 ng/mL. The concentration were chosen in the manner to cover the 
standard curve range of microarray and ELISA used for cytokine level determination. 
Prior to analysis the spiked samples were frozen at - 80ºC. 
 
6.3 Results 
Multiplex assay performance was compared with sandwich ELISA assay. Overall 78 
sera were measured using both technologies. In case of A there was only one value 
detectable by both technologies. Thus, in order to perform correlation analysis 10 
human serum spiked samples was prepared. Subsequently levels of A, C, D and F 
were measured in the spiked samples. The results from spiked samples measurements 
were pooled with the results from the 78 sera analyzed previously and subjected to 
linear regression analysis. The results are shown in Figure 23. The correlation 
coefficients (R2) for A, B, C, D, E, and F were 0.90, 0.60, 0.93, 0.96, 0.94 and 0.95 
respectively.  
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Figure 23: Correlation of antibody array and ELISA procedures. Cytokines in 78 sera 
and 10 spiked samples were quantified in parallel using either antibody microarray or 
ELISA. Data from these two analyses were plotted against each other and the 
correlation coefficients determined by linear regression analysis. 
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med oThe correlation analysis was perfor nly when the values were detectable by both 
technologies. When the values were detectable by one technique only, they were 
om  in the correlation analysis. Consequently the correlation was performed for 6, 
26, 20, 14, 26 and 14 samples for A, B, C, D, E and F respectively (Figure 23). 
 
6.4 iscussion 
The ip as fo  C , nd F showed very good correlation with 
individual ELISAs for the same analytes. The correlation coefficients were 0.90, 0.93, 
ite the fact that Abs used in both 
rrelation with ELISA was lower (0.60). This could be 
with sandwich immunoassay and possibly 
ance the interference of rheumatoid factors 
ilic antibodies often associated with 
tory diseases, which can recognize animal and human 
e or –negative results are generated 
 the presence of soluble receptor. Maybe 
receptor is biased by multiplex format. That 
can also cause false high or low cytokine level different for multiplex and single 
ELISA.  
 
The results described demonstrate the applicability of protein microarray to monitor 
simultaneously several analytes per sample. Good correlation between protein 
microarray and ELISA shows its potential to replace ELISA as a cost-effective and 
high throughput screening tool. ELISA allows for the measurement of one analyte per 
sample only, while using the multiplex approach from the same amount of sample the 
information of many analytes can be obtained. However B assay indicates that the 
measurements performed with different technologies not always give the same results. 
Additional analysis is required to explain these findings for instance, spike-recovery 
investigations to access the influence of matrix on the measurements performed with 
both techniques. 
 
 
 
itted
D
mult lex say r A, , D E a
0.96, 0.94 and 0.95 respectively. For B assay, desp
cases were the same, the co
explained by the problems often met 
magnified by assay multiplexing. For inst
or naturally occurring human heteroph
autoimmune or inflamma
immunoglobulin. Consequently false-positiv
(Hennig et al. 2000). Another reason could be
the binding affinity of B to this soluble 
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7 Application of antibody microarray to evaluate analytes in rheumatic 
ples. 
7.1 roduction 
The m  validated in chapter 5 was used to measure A, B, C, D, E and F 
serum concentrations in samples from the patients diagnosed with RA, other 
rheum ic diseases and control human sera. The goals were to investigate whether 
multiplex d microarray could be applied to real samples measurement and to conduct 
an exploratory study to assess whether those biomarkers could be relevant in 
diagnosis and monitoring of RA.  
7.2 aterials and methods 
7. Subjects and samples   
The serum samples were obtained from Felix Platter-Spital and Kantonsspital Aarau. 
This study was approved by ethic Committee (Study protocol EKBB 212/01). 
Studied samp mples from patients diagnosed with RA and 13 
samples from patients diagnosed with other rheumatic diseases such as polymylagia 
=1), Seronegative 
pondylarthropathie (n=1). Characteristics of the patients populations are shown in 
able 22.  
able 22: Patients characteristics. Data presented as mean ± SD.  
sam
Int
ultiplex assay
at
e
M
2.1 
les consisted of 35 sa
rheumatica (PMR) (n=3), juvenile rheumatoid arthritis (JRA) (n=1), connective tissue 
disease (CTD) (n=3), giant cell arteritis (n=1), vasculitis (n=2), undefined 
eronegative polyarthitis (n=1), low back pain (ns
S
T
 
T
                                                                  RA (n=35)        Non RA (n=13) 
Women/men             29/6   8/5 
Age (years)         61.8 ± 15.1         58.6 ± 14.5 
Disease duration (years)         9.7 ± 9.2   NA 
RF positive patients           22/35              2/13 
DMARDS  treated patients           34/35   7/13 
SD- andard deviast tion 
RF-rheumatoid factor 
DMARDS-disease modifying anti-rheumatic drugs 
NA- not assessed 
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Information about patient’s extraarticular manifestations (bone erosions, skin changes, 
pleuropulmonary manifestations, heart disease, Raynaud’s phenomenon, Sjörgen’s 
syndrome, rheumatoid vasculitis, osteoporosis and major joint replacement) were also 
collected (data not shown). 
 
7.2.2 Multiplex assay 
The serum concentrations of A, B, C, D, E and F were measured with the protein 
microarray validated in chapter 5. In case of A, C, F, for the values that were below 
limit of quantification (blq), the high sensitivity quantikine ELISA kit was used for 
samples measurements. The quantikine sensitivity was 0.125, 0.156 and 0.5 pg/mL 
r of A, C and F respectively. 
ata showed the difference for 5 analytes levels (B, C, D, E and F) 
etween the two groups (Table 23).  
 
 
fo
 
7.2.3 Data analysis 
Analysis of the data was performed using one way Anova analysis (Kempthorne O 
1983). The results were considered significant when the p values was less then 5 % 
(p<0.05). 
 
7.3 Results   
Mean values for each of the six analytes were calculated for the RA and non RA 
patients. These d
b
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Table 23: Serum concentrations of A, B, C, D, E and F for RA versus non-RA 
patients. Data is presented as mean and log (mean) and their SD respectively.  
RA Non RA 
Ana te ly MEAN 
[ng/ml] 
SD 
[ng/ml] 
LOG 
(MEAN) 
LOG 
 (SD) 
MEAN 
[ng/ml] 
SD 
[ng/ml] 
LOG 
(MEAN) 
LOG 
(SD) 
A 0.0002 0.0005 -3.634 -3.585 0.0004 0.001 -3.394 -3.101 
B 1.074 2.160 0.031 0.334 0.140 0.112 -0.853 -0.950 
C 0.090 0.160 -1.045 -0.796 0.004 0.007 -2.447 -2.162 
D 0.070 0.162 -1.157 -0.791 0.029 0.057 -1.539 -1.241 
E 0.551 0.430 -0.259 -0.366 0.243 0.240 -0.615 -0.620 
F 0.140 0.312 -0.853 -0.505 0.002 0.002 -2.621 -2.653 
SD-standard deviation 
 
Subsequently, the statistical Anova  analysis included the comparison of three 
patient’s groups: RA versus non RA, Rheumatoid factor (RF) positive versus RF 
 
f the 
tie s are hown able 24. The 
nifican  patients 
.00  and ively)  
e n 
(non RA) (non RA)
Mean 
(RA) 
Std 
(RA) p-value(RA) 
negative, bone erosion positive versus bone erosion negative. The analysis was
s of iperformed in regard to serum levels of six analyte nterest. The results o
comparison of RA and non RA rheumatic pa nt s  in T
concentrations of B, C, E and F in serum were sig tly higher in RA
(p<0.0022, p<0.0107, p<0 24 p<0.0057 respect . 
 
Table 24: One way Anova analysis for RA versus non RA patients. 
M a Std 
Column ID 
log(A) -3.7043 0.4199 -3.7741 0.2949 0.5207
log(B) -0.9733 0.3361 -0.3847 0.6171 0.0022
log(C) -2.8904 0.6490 -1.9610 1.1897 0.0107
log(D) -1.7916 0.3407 -1.5526 0.4979 0.1182
log(E) -0.8737 0.5469 -0.3988 0.4164 0.0024
log(F) -2.7765 0.3848 -1.8638 1.1022 0.0057
 
The results from the comparison of RF positive versus RF negative patients are shown 
in Table 25. There was a significant difference between this two groups of patients for 
 
 
 
B, C and F (p<0.0210, p<0.0325, p<0.0109) respectively. 
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Table 25: One way Anova analysis for RF positive versus RF negative patients. 
Column ID 
Mean 
(non RF) 
Std 
 (non RF) 
Mean 
(RF) 
Std 
(RF) p-value(RF) 
log(A) -3.7583 0.3472 -3.7401 0.3323 0.8038
log(B) -0.8047 0.4094 -0.3316 0.6992 0.0210
log(C) -2.6150 0.9245 -1.9542 1.2258 0.0325
log(D) -1.7425 0.3755 -1.4801 0.5300 0.1174
log(E) -0.6588 0.5103 -0.4005 0.4834 0.2099
log(F) -2.5858 0.7778 -1.7294 1.1213 0.0109
 
Table 26 shows the results of the comparison between patients with erosions and 
t on. There was a significant difference for B and C between this 
One way Anova analysis for patients diagnosed with erosion (E) versus non 
Column ID 
Mean 
(non E) 
Std 
(non E) 
Mean 
(E) 
Std 
(E) 
p-value 
(Erosions) 
patien s without erosi
two groups (p<0.0105 and p<0.0220).  
 
Table 26: 
erosions patients (non E). 
log(A) -3.7737 0.3331 -3.7351 0.3329 0.6906
log(B) -0.7566 0.4674 -0.3132 0.6738 0.0105
log(C) -2.5707 0.9646 -1.8236 1.2127 0.0220
log(D) -1.6861 0.3879 -1.5425 0.5438 0.2946
log(E) -0.6119 0.5004 -0.4356 0.4880 0.2235
lo 0.8622 -1.8513 1.1709 0.0979g(F) -2.3499
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7.4 Discussion 
Sta tical analysis rm ea vid al ow ign
difference in the serum of B (p<0.0022), C (p<0.0107), E (p<0.0024) 
and F (p<0.0057) between RA and other arthritic patients. Additionally, when 
comparing RF positive with RF negative patient populations, a statistical difference 
was obser the  of .02 p< ) a <0 Fi
served in the concentration levels of B (p<0.0105) and C 
<0.0220) in patients with and without bone erosions.  
xploratory. Additional 
xperiments are required to further validate the discriminating power of selected panel 
uired to confirm 
wheth d F ar m  the osis monitoring of RA 
sion and treatment t fil ngoing. Thus itional re
 will be described i sis.
nal analysis using l lgor n am to create 
hite, Chan, & 
odel could then be performed on a larger 
ple size, and valuable information on the sensitivity and specificity of the 
bined biomarkers for identifying RA patients would be obtained. It could be that 
ce 
five biomarkers rather tha ll set o . Alter y, se ity and specificity 
improv e f lyt  c
rkers on the microar
 
tis  perfo ed for ch indi ual an yte sh ed a s ificant 
 concentration 
ved in  levels  B (p<0 10), C ( 0.0325 nd F (p .0109). nally, a 
difference was also ob
(p
 
The obtained results demonstrated the applicability of the protein microarray to 
measure and compare  the concentration levels of selected analytes within samples 
obtained from patient populations. Additionally, the differences observed in the serum 
levels of B, C, E and F demonstrates the feasibility of the protein microarray format as 
a tool for identifying, confirming or validating  biomarkers in clinical samples. 
Although promising, these findings are, however, just e
e
of biomarkers. Additional is on ger sa size a eqanalys a lar mple re r
er B, C, E an e valid bio arkers for  diagn  or the 
progres . A paten ing is o , no add sults or 
analysis n this the    
 
Additio earning a ithms o training s ple sets models 
based on the expression profiles of the six biomarkers, followed by testing these 
models on blind samples would demonstrate the discriminating power of the 
combined biomarker approach for separating the patient groups (W
Zhang 2004). Further blind testing of the m
sam
com
the best sensitivity and specificity is obtained with a model combining for instan
n the fu f six nativel nsitiv
could be further ed h with t  addition o other ana es to the urrent set of 
bioma ray.  
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8 General discussion 
he aim of this thesis was to examine whether protein microarrays can be applied in 
teins (A, B, C, D, E, F) which were described 
 the literature to be associated with RA were selected. A protein microarray for the 
s prote icroarray was then assessed and finally 
validated with real sample me
oncept of protein mi  wa d  m ys, which e
easurement of mRNA expression level and enes in a 
iment (Schena et al The h sev sons why 
icroarray approach cannot be similarly adapted for the development of protein 
icroarrays. Firstly, DNA molecules are much more robust and easy to handle than 
olecules are physically and chemically similar, allowing 
anufacturing and assay procedures, and finally DNA reactivity 
in DNA microarrays is simple and depends only on 
ontrast to DNA, protein binding depends not only on 
ary sequence, but also on tertiary structure, which is far more vulnerable to 
Wilson & Nock 2002). During the dispensing and 
tion process, the proteins must maintain the integrity of their three-
ensional structures. Despite these difficulties many research groups have worked 
ent of various protein microarray platforms for a range of 
ations. This thesis describes the process of protein microarray development and 
onitoring of biomarkers in serum samples. 
r 3, the development of the protein microarray on a glass slide treated with 
ODP was described. This platform utilized a glass slide with an evanescent wave 
e that for DNA arrays are known to provide 100 times signal 
T
the drug development process to monitor biomarkers in preclinical and clinical 
studies. In order to demonstrate the feasibility of this approach, RA was chosen as a 
model for proof of concept. Several pro
in
simultaneous measurement of the disease concentrations of those proteins was 
developed. The robustness of thi in m
 measure nts. 
 
The c croarrays s inspire  by DNA icroarra nable 
the m of thous s of g single 
exper . 1995). re are, owever, eral rea DNA 
m
m
proteins. Secondly, DNA m
unification of m
(hybridization) exploited 
nucleotide sequence. In c
prim
degradation than DNA (
immobiliza
dim
on the developm
applic
validation for the m
 
In chapte
guid  property, 
amplification (Neuschafer et al. 2003). This feature presented the possibility to 
produce a sensitive tool for parallel protein measurements. The main drawback of 
using this approach was that surface treatment and all assay processing were 
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performed manually. This probably had a major contribution to the large variability 
observed between chips, and consequently the sensitivity level was inadequate to 
measure analytes of interest. The technique needed to be automated in terms of 
surface treatment and assay processing, however, at that time there was no robotic 
quid handling systems for processing protein microarrays in the market. The existing 
 neck tips for antibody printing devices, 
rovided the option of using a 96-well plate format for developing a protein 
 be measured in a large number of samples.  
During the development of the microarray in a 96-well plate, issues commonly faced 
ny immunoassay (such as antibody match-pair, matrix and 
li
systems for DNA microarrays fabrication utilized the plastic tubing equipment which 
could not be directly applied to proteins. The main reason for that was the ‘sticky’ 
nature of proteins (e.g. proteins clog the robots fluidic systems by sticking to the 
inside of the tubing) (Mitchell 2002). The proteins simply stayed attached to the 
inside tubing. Consequently, the lack of appropriate sensitivity, together with the time 
consuming process of chemically treating the surface, the complicated ODP synthesis 
procedure, and the lack of automation did not provide the required flexibility, 
reproducibility and robustness suitable for quantitative measurements. For all these 
reasons efforts towards the development of a protein microarray on a glass slide 
format were discontinued.  
The appearance on the market of long
p
microarray. Polystyrene 96-well plates are strongly established solid supports used for 
immunoassays (e.g., ELISA technique). The surface chemistry is standardized and 
optimized for antibody binding, and the assay processing can be fully automated. 
Therefore, the decision to adapt a RA protein microarray to this well characterized 
format was taken. The main advantage of this approach is the utilisation of 
commercially available 96-well plate and standard laboratory equipment together with 
standard plate washers. This aspect is of particular importance in cases when the 
samples from drug trials need to be analyzed in different laboratories. On the other 
hand the 96-well plate format limits the number of analytes multiplexed per well. This 
fact predisposed the 96-well platform as a monitoring rather then discovery tool for a 
defined number of biomarkers to
with the development of a
assay format selection, cross reactivity, printing protocols and choice of signal 
detection system) were investigated. For the selection of matrix for calibrators 
preparation, FDA industry guidelines for pharmacokinetic immunoassays recommend 
immunoassay development in the same matrix as the analyzed samples (Findlay et al. 
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2000; Food and Drug Administration 2001). This approach is quite often problematic 
during immunoassay development because the presence of endogenous molecules of 
interest, which may interfere with measurements. In addition, other endogenous 
molecules such as soluble receptors and heterophilic antibodies bind to the assay 
agents leading to false positive or false negative results (Hennig et al. 2000). To 
activity with the assay 
agents is negligible.  
re
avoid endogenous molecule interference, commercially available ELISA kits use 
analyte of interest free buffers for standard curve preparation. The 96-well microarray 
in this thesis was developed to measure human serum samples. Consequently human 
serum was the first choice for a matrix to prepare the standard curve. However, 
because the linearity of standard curve for some analytes could not be obtained using 
human serum as matrix, in parallel standard curve was prepared in analyte free buffer. 
Though, when the buffer was used for standard curve preparation the recovery of 
spiked samples failed to fulfil  the assay acceptance criteria. For instance, IL-1β assay 
accuracy of human serum spiked samples was ∼50%. In general this approach, creates 
an artificial assay environment which does not contain the same molecules as when 
using authentic sample matrix. This could introduce measurement mistakes as the 
protein functionality often depends on partnership with other proteins (Colburn 2003; 
Zhu & Snyder 2003). Based on these results the assay was developed in the pool of 
human sera that contained low levels of the measured analytes. The question is what if 
such a pool can not be selected for all the analytes of interest? One alternative could 
be to select pools of sera from other species in which cross re
re
Talking about the choice of the detection system, the reason for which 
chemiluminescent was selected, was dictated by the 96-well plate format. The scanner 
that would allow to image the fluorescent signal in 96-well plate at that time was not 
available on the market. Instead the CCD camera commonly used for many laboratory 
applications could be utilized for chemiluminescent detection in 96-well plate. 
However chemiluminescent detection has its drawback. Firstly the readout has to be 
done immediately after the addition of the chemiluminescent substrate, as the 
enzymatic reaction progresses with time. Otherwise, the signal generated from each 
spot could contaminate signals generated from neighbouring spots. In the future 
fluorescent detection mainly because it is easy to perform, stable, gives the 
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opportunity for multiple measurement over the time and is compatible with the signal 
amplification methods, could be adapted to the microarray in 96-well plate. 
 
Currently, there are no existing guidelines for the validation of biomarker and 
antibody microarrays. Standardised guidelines would be crucial for reliable multiplex 
measurements, especially when samples are analysed in different study centres 
(Kumble 2003). Thus, in order to validate the robustness and reproducibility of the 
developed protein microarray, a protocol based on the existing FDA regulatory 
guidelines for pharmacokinetic immunoassays (Findlay et al. 2000) was created (Food 
l. 2002; 
and Drug Administration 2001). A spike-recovery validation test was elaborated and 
run over 3 days. This validation study demonstrated the microarray to be both 
quantitative and reproducible at assay working ranges covering the relevant 
physiological concentrations of the analytes, with an accuracy between 70-130%, and 
assay precision less than 30%. However, problems could arise if in future the FDA 
releases a guideline which does not match with the above set criteria. Consequently, 
all steps in microarray development should be optimized in order to easily meet any 
future FDA guidelines. 
 
ELISA technique has been widely used for protein quantification since its 
introduction by Engvall and Perlaman in 1971 (Engvall & Perlman 1971). 
Subsequently, ELISA if often treated as a reference standard when investigating the 
performance of protein microarrays (Kellar et al. 2001; Mezzasoma et a
Prabhakar, Eirikis, & Davis 2002; Woodbury, Varnum, & Zangar 2002). The 
microarray developed and validated in this thesis was also compared with the single 
ELISA. Correlation coefficients between the two technologies was calculated for each 
analyte in sera collected from a total of 78 individuals representing either rheumatic or 
healthy patients. High correlation coefficients were obtained for five out of six 
analytes measured (0.90, 0.93, 0.96, 0.94 and 0.95 for A, C, D, E, and F respectively). 
Generally, with assays based on immunochemical methods, it is common to see 
variations in absolute quantification between methods, and improving their 
comparability is a recognizable challenge (Bidart et al. 1999; Woodbury, Varnum, & 
Zangar 2002). That is why results obtained with single ELISA and multiplex assays 
do not always agree. Despite using the same antibodies to prepare both microarray 
and ELISA methods, for B the correlation coefficient was only 0.60. B could bind to 
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the soluble receptor or its measurement could be biased by the heterophilic antibodies 
present in serum (Hennig et al. 2000). Perhaps, this events could occur differently in 
single compared to multiplexed set ups. In order to explore this matrix effect for both 
techniques, additional analysis of spike-recovery of samples is required.  
 
When choosing between techniques used for analysing samples from clinical studies, 
it is important to consider sample amounts available and the quantity of information 
which can be generated from the same amount of sample. Single ELISA allows for 
the analysis of one analyte per assay, thus many assays are required for many 
analytes. This dramatically increases the cost and sample volume requirements for 
generating a single data point when compared to a multiplex ELISA approach. On the 
other hand there is a risk of cross reactivity between the antibody pairs and proteins 
other than the target proteins when using the multiplex approach. This could represent 
a potential limiting factor for multiplex assay application. Sometimes, however, 
depending on the application, it will not be necessary to develop and utilise a protein 
microarray approach. There could be cases where the application of a single ELISA 
should be 
alidated on a larger patient population. Nevertheless, the potential for the 
assays to measure a certain number of samples will be more reasonable from an 
economical point of view. In other cases, if commercial microarrays to measure 
certain analytes are available, the microarray development process would not be 
worth the investment in time and cost.  
 
The applicability of the developed protein microarray to analyze samples from a 
cohort of patients diagnosed with either RA or other rheumatic diseases was 
investigated in chapter 7. The results showed a significant differences in the serum 
concentration levels of B (p<0.0022), C (p<0.0107), E (p<0.0024) and F (p<0.0057) 
between RA and other arthritic patients. These findings, however, should be 
considered as exploratory only, due to the small sample population size. Differences 
in the measured levels of B, C, E and F between  respective groups 
v
identification of a panel of biomarkers that could differentiate RA from other 
rheumatic diseases would revolutionize the RA diagnosis. 
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9 Conclusion and future perspective 
In this thesis, a multiplexed assay for quantitation of A, B, C, D, E and F in human 
sera has been described and validated. It is proposed that miniaturized and 
multiplexed immunoassays will offer a cost effective and efficient manner for 
validating and monitoring biomarkers during the drug development process. In 
preclinical studies it could find its utility in the validation of biomarkers identified by 
genomics and proteomics. Microarrays consisting of validated panels of biomarkers 
can then be used in clinic for the diagnosis, prognosis and monitoring of disease 
progression, in the monitoring of clinical responses to therapeutic intervention such as 
in efficacy determination and safety monitoring, as well as in the stratification of 
atient populations. Another direction in which protein microarrays will continue to p
be developed is in the investigation of protein function. Protein function arrays will be 
extremely useful for investigating the activities and binding properties of native 
proteins, especially in the screening of protein-binding small molecules including 
potential drug candidates. 
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LIST OF ABBREVIATIONS 
 
Ab   antibody 
BCA  biochip arrayer 
CCD  charge coupled device 
CSF  cerebrospinal fluid 
FDA  food and drug administration 
HRP  horse radish peroxidise 
HSPs   heat shock proteins  
mAb  monoclonal antibody 
MHC  major histocompatibility complex 
ODP  octadecyl phosphoric acid ester 
RA  Rheumatoid arthritis 
 
RF  rheumatoid factor 
SAM  self assembled monolayer 
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